#compound_ID,Exp_label(HGMMS/HGMMI),chemical_name,SMILES,reaction_type,direct_metabolite,final_metabolite,reference_year_month,reference_title,DOI
TS0001,HGMMS,nicardipine,CC1=C(C(C(=C(N1)C)C(=O)OCCN(C)CC2=CC=CC=C2)C3=CC(=CC=C3)[N+](=O)[O-])C(=O)OC,reduction,CC1=C(C(OC)=O)C(C2=CC(N)=CC=C2)C(C(OCCN(CC3=CC=CC=C3)C)=O)=C(C)N1,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0002,HGMMS,risperidone,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,hydrolysis,CC1=C(CCN2CCC(C(C(C=CC(F)=C3)=C3O)=O)CC2)C(N4CCCCC4=N1)=O,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0003,HGMMS,tolcapone,CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-],"reduction, acetylation",Cc1ccc(C(c2cc(NC(C)=O)c(O)c(O)c2)=O)cc1,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0004,HGMMS,azathioprine,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0005,HGMMS,entacapone,CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0006,HGMMS,exemestane,CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0007,HGMMS,nimodipine,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0008,HGMMS,capsaicin,CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0009,HGMMS,ethacrynic acid,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0010,HGMMS,vorinostat,C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO,reduction,O=C(CCCCCCC(N)=O)NC1=CC=CC=C1,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0011,HGMMS,dolasetron,C1C2CC3CC(CC1N3CC2=O)OC(=O)C4=CNC5=CC=CC=C54,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0012,HGMMS,mycophenolate mofetil,CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC,hydrolysis,CC1=C(OC)C(CC=C(CCC(O)=O)C)=C(O)C2=C1COC2=O,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0013,HGMMS,zidovudine,CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)N=[N+]=[N-],unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0014,HGMMS,allopurinol,C1=C2C(=NC=NC2=O)NN1,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0015,HGMMS,bisacodyl,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0016,HGMMS,estradiol,CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0017,HGMMS,famciclovir,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0018,HGMMS,flutamide,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0019,HGMMS,hydrocortisone,CC12CCC(=O)C=C1CCC3C2C(CC4(C3CCC4(C(=O)CO)O)C)O,"reduction, desmolysis",OCC(C1(CCC2C1(CC(C3C2CCC4=CC(CCC34C)=O)O)C)O)O,O=C1CCC2C1(CC(C3C2CCC4=CC(CCC34C)=O)O)C,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0020,HGMMS,methylprednisolone,CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0021,HGMMS,metronidazole,CC1=NC=C(N1CCO)[N+](=O)[O-],unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0022,HGMMS,nabumetone,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,reduction,CC(CCC1=CC2=C(C=C(OC)C=C2)C=C1)O,NONE,2016/08,Human gut microbiota plays a role in the metabolism of drugs,10.5507/bp.2016.039
TS0023,HGMMS,pantoprazole,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0024,HGMMS,progesterone,CC(=O)C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34C)C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0025,HGMMS,spironolactone,CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C,hydrolysis,SC1CC2=CC(CCC2(C)C3C1C4CCC5(CCC(O5)=O)C4(C)CC3)=O,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0026,HGMMS,sulfasalazine,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,reduction,O=S(NC1=CC=CC=N1)(C2=CC=C(N)C=C2)=O,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0027,HGMMS,tinidazole,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0028,HGMMS,fluoxetine,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0029,HGMMS,misoprostol,CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O,hydrolysis,CCCCC(O)(C)CC=CC1C(CC(C1CCCCCCC(O)=O)=O)O,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0030,HGMMS,megestrol acetate,CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0031,HGMMS,capecitabine,CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O,hydrolysis,CCCCCOC(NC1=NC(NC=C1F)=O)=O,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0032,HGMMS,chenodeoxycholic acid,CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C,dehydroxylation,CC(C1CCC2C1(C)CCC3C2CCC4C3(C)CCC(O)C4)CCC(O)=O,NONE,1979/11,Transformation of Chenodeoxycholic Acid and Ursodeoxycholic Acid by Human Intestinal Bacteria,10.1016/S0016-5085(79)80079-7
TS0033,HGMMS,clofazimine,CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl,dechlorination,CC(N=C1C=C2C(C=C1NC3=CC=CC=C3)=NC4=CC=CC=C4N2C5=CC=C(Cl)C=C5)C,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0034,HGMMS,clonazepam,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,reduction,O=C1CN=C(C2=CC=CC=C2Cl)C(C=C(N)C=C3)=C3N1,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0035,HGMMS,cortisone acetate,CC(=O)OCC(=O)C1(CCC2C1(CC(=O)C3C2CCC4=CC(=O)CCC34C)C)O,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0036,HGMMS,dantrolene.na,C1C(=O)N=C(N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-])[O],unknown,NONE,NONE,1985/08,Reduction of dantrolene by enteric bacteria,10.1248/yakushi1947.105.8_770
TS0037,HGMMS,duloxetine,CNCCC(C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0038,HGMMS,fludrocortisone acetate,CC(=O)OCC(=O)C1(CCC2C1(CC(C3(C2CCC4=CC(=O)CCC43C)F)O)C)O,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0039,HGMMS,iloperidone,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0040,HGMMS,lorazepam,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0041,HGMMS,nilutamide,CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0042,HGMMS,nitisinone,C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-],unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0043,HGMMS,nitrofurantoin,C1C(=O)NC(=O)N1N=CC2=CC=C(O2)[N+](=O)[O-],unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0044,HGMMS,oxazepam,C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O,dehydroxylation,O=C(NC1=C2C=C(Cl)C=C1)CN=C2C3=CC=CC=C3,NONE,2010/06,A novel reductive transformation of oxazepam to nordiazepam observed during enzymatic hydrolysis,10.1093/jat/34.5.243
TS0045,HGMMS,prasugrel,CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0046,HGMMS,probenecid,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0047,HGMMS,rifabutin,CC1C=CC=C(C(=O)NC2=C3C(=NC4(N3)CCN(CC4)CC(C)C)C5=C6C(=C(C(=C5C2=O)O)C)OC(C6=O)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0048,HGMMS,sulfamethoxazole,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0049,HGMMS,acecainide,CC[N](CC)CCNC(=O)c1ccc(NC(C)=O)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0050,HGMMS,alprenolol,C=CCc1ccccc1OCC(O)C[NH]C(C)C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0051,HGMMS,artemisinin,CC1CCC2C(C)C(=O)OC3OC4(C)CCC1C32OO4,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0052,HGMMS,benzbromarone,CCc1oc2ccccc2c1C(=O)c1cc(Br)c([O])c(Br)c1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0053,HGMMS,benzthiazide,NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)[N]S2(=O)=O,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0054,HGMMS,betamethasone acetate,CC(=O)OCC(=O)C1(O)C(C)CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC21C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0055,HGMMS,betamethasone valerate,CCCCC(=O)OC1(C(=O)CO)C(C)CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC21C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0056,HGMMS,bezafibrate,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)[O],unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0057,HGMMS,camylofine dihydrochloride,CC[N](CC)CCNC(C(=O)OCCC(C)C)c1ccccc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0058,HGMMS,carbetapentane citrate,CC[N](CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0059,HGMMS,carisoprodol,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0060,HGMMS,celecoxib,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0061,HGMMS,chlormezanone,CN1C(=O)CCS(=O)(=O)C1c1ccc(Cl)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0062,HGMMS,clemastine fumarate,C[N]1CCCC1CCOC(C)(c1ccccc1)c1ccc(Cl)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0063,HGMMS,clemizole,Clc1ccc(Cn2c(C[N]3CCCC3)nc3ccccc32)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0064,HGMMS,cyproterone acetate,CC(=O)OC1(C(C)=O)CCC2C3C=C(Cl)C4=CC(=O)C5CC5C4(C)C3CCC21C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0065,HGMMS,danazol,C#CC1(O)CCC2C3CCC4=Cc5oncc5CC4(C)C3CCC21C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0066,HGMMS,deflazacort,CC(=O)OCC(=O)C12[N]=C(C)OC1CC1C3CCC4=CC(=O)C=CC4(C)C3C(O)CC12C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0067,HGMMS,diflorasone diacetate,CC(=O)OCC(=O)C1(OC(C)=O)C(C)CC2C3CC(F)C4=CC(=O)C=CC4(C)C3(F)C(O)CC21C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0068,HGMMS,digitoxin,CC1OC(OC2C(O)CC(OC3C(O)CC(OC4CCC5(C)C(CCC6C5CCC5(C)C(C7=CC(=O)OC7)CCC65O)C4)OC3C)OC2C)CC(O)C1O,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0069,HGMMS,diltiazem,COc1ccc(C2Sc3ccccc3N(CC[N](C)C)C(=O)C2OC(C)=O)cc1,hydrolysis,COc1ccc(C2Sc3c(N(CCN(C)C)C(C2O)=O)cccc3)cc1,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0070,HGMMS,diphenylpyraline,C[N]1CCC(OC(c2ccccc2)c2ccccc2)CC1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0071,HGMMS,ethopropazine,CCN(CC)C(C)CN1c2ccccc2Sc2ccccc21,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0072,HGMMS,ethoxzolamide,CCOc1ccc2nc(S(N)(=O)=O)sc2c1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0073,HGMMS,famprofazone,CC(C)c1c(CN(C)C(C)Cc2ccccc2)n(C)n(-c2ccccc2)c1=O,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0074,HGMMS,fenofibrate,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0075,HGMMS,fenspiride,O=C1NCC2(CC[N](CCc3ccccc3)CC2)O1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0076,HGMMS,gliclazide,Cc1ccc(S(=O)(=O)[N]C(=O)NN2CC3CCCC3C2)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0077,HGMMS,idebenone,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0078,HGMMS,irsogladine maleate,Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0079,HGMMS,levamisole,c1ccc(C2CN3CCSC3=N2)cc1,hydrolysis,SCCN(C(N1O)=O)CC1c2ccccc2,NONE,1991/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.3109/00498259109039513
TS0080,HGMMS,linagliptin,CC#CCn1c(N2CCCC([N])C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,unknown,NONE,NONE,2019/06,Metabolism of levamisole an anti-colon cancer drug by human intestinal bacteria,10.1038/s41586-019-1291-3
TS0081,HGMMS,lofexidine,CC(Oc1c(Cl)cccc1Cl)C1=[N]CCN1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0082,HGMMS,melphalan,[N]C(Cc1ccc([N](CCCl)CCCl)cc1)C(=O)[O],unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0083,HGMMS,methsuximide,CN1C(=O)CC(C)(c2ccccc2)C1=O,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0084,HGMMS,methylphenidate,COC(=O)C(c1ccccc1)C1CCCC[N]1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0085,HGMMS,methysergide maleate,CCC(CO)NC(=O)C1C=C2c3cccc4c3c(cn4C)CC2[N](C)C1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0086,HGMMS,metitepine maleate,CSc1ccc2c(c1)C(N1CC[N](C)CC1)Cc1ccccc1S2,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0087,HGMMS,nafronyl oxalate,CC[N](CC)CCOC(=O)C(Cc1cccc2ccccc12)CC1CCCO1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0088,HGMMS,naftopidil,COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0089,HGMMS,naloxone,C=CCN1CCC23c4c5ccc(O)c4OC2C(=O)CCC3(O)C1C5,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0090,HGMMS,neostigmine bromide,CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0091,HGMMS,nicergoline,COC12CC(COC(=O)c3cncc(Br)c3)C[N](C)C1Cc1cn(C)c3cccc2c13,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0092,HGMMS,norgestimate,C#CC1(OC(C)=O)CCC2C3CCC4=CC(=NO)CCC4C3CCC21CC,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0093,HGMMS,noscapine,COc1ccc2c(c1OC)C(=O)OC2C1c2c(cc3c(c2OC)OCO3)CCN1C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0094,HGMMS,olmesartan medoxomil,CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0095,HGMMS,orphenadrine citrate,Cc1ccccc1C(OCC[N](C)C)c1ccccc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0096,HGMMS,paclitaxel,CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0097,HGMMS,papaverine,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0098,HGMMS,penbutolol sulfate,CC(C)(C)[N]CC(O)COc1ccccc1C1CCCC1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0099,HGMMS,pericyazine,N#Cc1ccc2c(c1)N(CCC[N]1CCC(O)CC1)c1ccccc1S2,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0100,HGMMS,phenazopyridine,Nc1ccc(N=Nc2ccccc2)c(N)n1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0101,HGMMS,pidotimod,O=C1CCC(C(=O)N2CSCC2C(=O)[O])N1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0102,HGMMS,pranoprofen,CC(C(=O)[O])c1ccc2c(c1)Cc1cccnc1O2,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0103,HGMMS,procarbazine,CNNCc1ccc(C(=O)NC(C)C)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0104,HGMMS,racecadotril,CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0105,HGMMS,ranitidine,CNC(=C[N+](=O)[O-])NCCSCc1ccc(C[N](C)C)o1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0106,HGMMS,rebamipide,O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)[O])c1ccc(Cl)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0107,HGMMS,rizatriptan benzoate,C[N](C)CCc1c[nH]c2ccc(Cn3cncn3)cc12,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0108,HGMMS,roxatidine acetate,CC(=O)OCC(=O)NCCCOc1cccc(C[N]2CCCCC2)c1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0109,HGMMS,sulfinpyrazone,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,reduction,O=C(C(CCSC1=CC=CC=C1)C(N2C3=CC=CC=C3)=O)N2C4=CC=CC=C4,NONE,1984/09,Role of the gut flora in the reduction of sulfinpyrazone in humans,PMID: 6470977
TS0110,HGMMS,sulpiride,CC[N]1CCC(CNC(=O)c2cc(S(N)(=O)=O)ccc2OC)C1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0111,HGMMS,tacrolimus,C=CCC1C=C(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C)=CC3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC,reduction,C=CCC1C=C(CC(CC(C2OC(C(C(N3CCCCC3C(OC(C(C(CC1=O)O)C)C(C)=CC4CCC(C(C4)OC)O)=O)=O)O)(C(CC2OC)C)O)OC)C)C,NONE,2019/03,Commensal Gut Bacteria Convert the Immunosuppressant Tacrolimus to Less Potent Metabolites,10.1124/dmd.118.084772
TS0112,HGMMS,tenatoprazole,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=CC(=N3)OC,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0113,HGMMS,thiothixene,CN(C)S(=O)(=O)c1ccc2c(c1)C(=CCCN1CC[N](C)CC1)c1ccccc1S2,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0114,HGMMS,tranilast,COc1ccc(C=CC(=O)Nc2ccccc2C(=O)[O])cc1OC,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0115,HGMMS,trimebutine maleate,CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0116,HGMMS,trimetazidine dihydrochloride,COc1ccc(CN2CC[N]CC2)c(OC)c1OC,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0117,HGMMS,valsartan,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0118,HGMMS,vilazodone,N#Cc1ccc2[nH]cc(CCCC[N]3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0119,HGMMS,vinpocetine,CCOC(=O)C1=CC2(CC)CCC[N]3CCc4c(n1c1ccccc41)C32,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TS0120,HGMMS,Sulindac,CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)/C1=C\C3=CC=C(S(C)=O)C=C3,reduction,CC1=C(C2=C(/C1=C\C3=CC=C(C=C3)SC)C=CC(F)=C2)CC(O)=O,NONE,1987/06,The reduction of sulphinpyrazone and sulindac by intestinal bacteria,10.3109/00498258709043976
TS0121,HGMMS,Digoxin,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,reduction,C[C@@H]1[C@@H](O)[C@@H](O)C[C@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)O[C@@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@@]7(C)[C@]6(O)CC[C@@H]7[C@H]8CC(OC8)=O)C4)C[C@@H]3O)C[C@@H]2O)O1,NONE,1982/08,Metabolism of digoxin and absorption site.,10.1111/j.1365-2125.1982.tb01976.x
TS0122,HGMMS,Sorivudine,C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O)/C=C/Br,hydrolysis,C1=C(C(=O)NC(=O)N1)/C=C/Br,NONE,1997/02,Intestinal anaerobic bacteria hydrolyse sorivudine producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil,10.1097/00008571-199702000-00005
TS0123,HGMMS,Lactulose,C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@]([C@H]2O)(CO)O)CO)O)O)O)O,unknown,NONE,NONE,1969/08,Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial,10.1056/NEJM196908212810803
TS0124,HGMMS,Levodopa,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,decarboxylation,NCCC1=CC(O)=C(O)C=C1,NONE,2019/06,Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism,10.1126/science.aau6323
TS0125,HGMMS,Flucytosine,C1=NC(=O)NC(=C1F)N,hydrolysis,C1=C(C(=O)NC(=O)N1)F,NONE,2003/05,An in vitro study on the active conversion of flucytosine to fluorouracil by microorganisms in the human intestinal microflora,10.1159/000069784
TS0126,HGMMS,Lovastatin,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,hydrolysis,O[C@H]1C[C@@H](C)C=C2[C@H]1[C@@H](CC[C@@H]3C[C@@H](O)CC(O3)=O)[C@@H](C)C=C2,CC[C@@H](C(O[C@H]1C[C@@H](C)C=C2[C@H]1[C@@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@@H](C)C=C2)=O)C,2014/09,Gut microbiota-mediated drug interactions between lovastatin and antibiotics,10.1124/dmd.114.058354
TS0127,HGMMS,Nicotine N-oxide,C[N+]1(CCCC1C2=CN=CC=C2)[O-],reduction,CN1CCC[C@H]1C2=CN=CC=C2,NONE,1970/09,Absorption of (-)-nicotine-l-N-oxide in man and its reduction in the gastrointestinal tract,10.1111/j.2042-7158.1970.tb12767.x
TS0128,HGMMS,Loperamide N-oxide,CN(C)C(=O)C(CC[N+]1(CCC(CC1)(C2=CC=C(C=C2)Cl)O)[O-])(C3=CC=CC=C3)C4=CC=CC=C4,reduction,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,NONE,1995/03,Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats dogs and humans,PMID: 7628301
TS0129,HGMMS,Brilliant Black,CC(=O)NC1=C2C(=C(C=C1)S(=O)(=O)[O-])C=C(C(=C2O)N=NC3=C4C=C(C=CC4=C(C=C3)N=NC5=CC=C(C=C5)S(=O)(=O)[O-])S(=O)(=O)[O])S(=O)(=O)[O],unknown,NONE,NONE,2019/04,Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota,10.1038/s41598-019-41894-8
TS0130,HGMMS,Sunset Yellow,C1=CC(=CC=C1N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O])O)S(=O)(=O)[O],unknown,NONE,NONE,2019/04,Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota,10.1038/s41598-019-41894-8
TS0131,HGMMS,Tartrazine,C1=CC(=CC=C1N=NC2C(=NN(C2=O)C3=CC=C(C=C3)S(=O)(=O)[O])C(=O)[O])S(=O)(=O)[O],unknown,NONE,NONE,2019/04,Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota,10.1038/s41598-019-41894-8
TS0132,HGMMS,Allura Red,CC1=CC(=C(C=C1S(=O)(=O)[O-])OC)N=NC2=C(C=CC3=C2C=CC(=C3)S(=O)(=O)[O])O,unknown,NONE,NONE,1978/03,Reduction of azo dyes by intestinal anaerobes,10.1128/aem.35.3.558-562.1978
TS0133,HGMMS,methyl orange,CN(C)C1=CC=C(C=C1)N=NC2=CC=C(C=C2)S(=O)(=O)[O],unknown,NONE,NONE,1978/03,Reduction of azo dyes by intestinal anaerobes,10.1128/aem.35.3.558-562.1978
TS0134,HGMMS,ponceau SX,CC1=CC(=C(C=C1N=NC2=C(C3=CC=CC=C3C(=C2)S(=O)(=O)[O])O)S(=O)(=O)[O])C,unknown,NONE,NONE,1978/03,Reduction of azo dyes by intestinal anaerobes,10.1128/aem.35.3.558-562.1978
TS0135,HGMMS,Sudan I,C1=CC=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O,reduction,NC1=C(O)C=CC2=CC=CC=C21,NC1=CC=CC=C1,2007/12,Anaerobic metabolism of 1-amino-2-naphthol-based azo dyes (Sudan dyes) by human intestinal microflora,10.1128/AEM.01410-07
TS0136,HGMMS,Sudan II,CC1=CC(=C(C=C1)N=NC2=C(C=CC3=CC=CC=C32)O)C,reduction,NC1=C(O)C=CC2=CC=CC=C21,CC1=CC(C)=C(N)C=C1,2007/12,Anaerobic metabolism of 1-amino-2-naphthol-based azo dyes (Sudan dyes) by human intestinal microflora,10.1128/AEM.01410-07
TS0137,HGMMS,Sudan III,C1=CC=C(C=C1)N=NC2=CC=C(C=C2)N=NC3=C(C=CC4=CC=CC=C43)O,reduction,NC1=C(O)C=CC2=CC=CC=C21,NC1=CC=C(N)C=C1,2007/12,Anaerobic metabolism of 1-amino-2-naphthol-based azo dyes (Sudan dyes) by human intestinal microflora,10.1128/AEM.01410-07
TS0138,HGMMS,Sudan IV,CC1=CC=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=CC4=CC=CC=C43)O)C,reduction,NC1=C(O)C=CC2=CC=CC=C21,NC1=CC(C)=C(N)C=C1,2007/12,Anaerobic metabolism of 1-amino-2-naphthol-based azo dyes (Sudan dyes) by human intestinal microflora,10.1128/AEM.01410-07
TS0139,HGMMS,ParaRed,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)[N+](=O)[O-])O,reduction,NC1=C(O)C=CC2=CC=CC=C21,NC1=CC=C([N+]([O-])=O)C=C1,2007/12,Anaerobic metabolism of 1-amino-2-naphthol-based azo dyes (Sudan dyes) by human intestinal microflora,10.1128/AEM.01410-07
TS0140,HGMMS,ponceau BS,C1=CC=C2C(=C1)C=CC(=C2N=NC3=C(C=C(C=C3)N=NC4=CC=C(C=C4)S(=O)(=O)[O])S(=O)(=O)[O])O,unknown,NONE,NONE,2004/04,Molecular cloning overexpression purification and characterization of an aerobic FMN-dependent azoreductase from Enterococcus faecalis,10.1016/j.pep.2003.12.016
TS0141,HGMMS,ponceau S,C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)[O])S(=O)(=O)[O])S(=O)(=O)[O])S(=O)(=O)[O],unknown,NONE,NONE,2004/04,Molecular cloning overexpression purification and characterization of an aerobic FMN-dependent azoreductase from Enterococcus faecalis,10.1016/j.pep.2003.12.016
TS0142,HGMMS,Ponceau 3R,CC1=CC(=C(C=C1C)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)[O])S(=O)(=O)[O])C,reduction,NC1=C2C=CC(S(=O)([O])=O)=CC2=CC(S(=O)([O])=O)=C1O,CC1=CC(C)=C(N)C=C1C,1979/03,Production of a mutagen from ponceau 3R by a human intestinal anaerobe,10.1128/iai.23.3.686-689.1979
TS0143,HGMMS,Ponceau 2R,CC1=CC(=C(C=C1)N=NC2=C3C=CC(=CC3=CC(=C2O)S(=O)(=O)O)S(=O)(=O)O)C,reduction,NC1=C2C=CC(S(=O)([O])=O)=CC2=CC(S(=O)([O])=O)=C1O,CC1=CC(C)=C(N)C=C1,1979/03,Production of a mutagen from ponceau 3R by a human intestinal anaerobe,10.1128/iai.23.3.686-689.1979
TS0144,HGMMS,Trypan Blue,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O])S(=O)(=O)[O])N)O)C)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O])S(=O)(=O)[O])N)O,reduction,NC1=C(O)C2=C(N)C=C(S(=O)([O])=O)C=C2C=C1S(=O)([O])=O,CC1=C(N)C=CC(C2=CC(C)=C(N)C=C2)=C1,2008/09,The reduction of azo dyes by the intestinal microflora,10.3109/10408419209114557
TS0145,HGMMS,Direct Black 38,C1=CC=C(C=C1)N=NC2=C(C3=C(C(=C(C=C3C=C2S(=O)(=O)[O])S(=O)(=O)[O])N=NC4=CC=C(C=C4)C5=CC=C(C=C5)N=NC6=C(C=C(C=C6)N)N)N)O,reduction,NC1=C(C2=C(C(N)=C(C=C2C=C1S(=O)(O)=O)S(=O)(O)=O)N)O,NC1=CC=C(C2=CC=C(N)C=C2)C=C1,1982/08,Metabolism of benzidine and benzidine-congener based dyes by human monkey and rat intestinal bacteria,10.1016/s0006-291x(82)80128-9
TS0146,HGMMS,Direct Red 2,CC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=CC=CC=C4C(=C3)S(=O)(=O)[O])N)C)N=NC5=C(C6=CC=CC=C6C(=C5)S(=O)(=O)[O])N,reduction,CC1=C(N)C=CC(C2=CC(C)=C(N)C=C2)=C1,NC1=C(N)C2=CC=CC=C2C(S(=O)(O[H])=O)=C1,1982/08,Metabolism of benzidine and benzidine-congener based dyes by human monkey and rat intestinal bacteria,10.1016/s0006-291x(82)80128-9
TS0147,HGMMS,Direct Blue 15,COC1=C(C=CC(=C1)C2=CC(=C(C=C2)N=NC3=C(C4=C(C=C(C=C4C=C3S(=O)(=O)[O])S(=O)(=O)[O])N)O)OC)N=NC5=C(C6=C(C=C(C=C6C=C5S(=O)(=O)[O])S(=O)(=O)[O])N)O,reduction,COC1=C(N)C=CC(C2=CC(OC)=C(N)C=C2)=C1,NC1=C(O)C2=C(N)C=C(S(=O)(O)=O)C=C2C=C1S(=O)(O)=O,1982/08,Metabolism of benzidine and benzidine-congener based dyes by human monkey and rat intestinal bacteria,10.1016/s0006-291x(82)80128-9
TS0148,HGMMS,Urolithin M-5,OC1=C(O)C(O)=C(C2=C(OC3=O)C(O)=C(O)C=C2)C3=C1,dehydroxylation,OC1=C(O)C(O)=C(C2=C(OC3=O)C=C(O)C=C2)C3=C1,NONE,2014/08,Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species,10.1039/c4fo00092g
TS0149,HGMMS,Ponceau 4R,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)[O])N=NC3=C(C=CC4=CC(=CC(=C43)S(=O)(=O)[O])S(=O)(=O)[O])O,unknown,NONE,NONE,1980/08,Reduction of sulphonated water-soluble azo dyes by micro-organisms from human faeces,10.1016/0015-6264(80)90187-x
TS0150,HGMMS,Red 2G,CC(=O)NC1=C2C(=CC(=C1)S(=O)(=O)[O])C=C(C(=C2O)N=NC3=CC=CC=C3)S(=O)(=O)[O],unknown,NONE,NONE,1970/12,The metabolism of azo compounds: a review of the literature,10.1016/s0015-6264(70)80455-2
TS0151,HGMMS,caffeic acid,C1=CC(=C(C=C1/C=C/C(=O)O)O)O,reduction,O=C(O)CCC1=CC=C(O)C(O)=C1,O=C(O)CCC1=CC=CC(O)=C1,2006/11,Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human faecal microbiota in vitro,10.1016/j.biopha.2006.07.084
TS0152,HGMMS,chlorogenic acid,C1[C@H]([C@H]([C@@H](C[C@@]1(C(=O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O)O,reduction,O=C(O)CCC1=CC=C(O)C(O)=C1,O=C(O)CCC1=CC=CC(O)=C1,2006/11,Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human faecal microbiota in vitro,10.1016/j.biopha.2006.07.084
TS0153,HGMMS,caftaric acid,C1=CC(=C(C=C1/C=C/C(=O)O[C@H]([C@H](C(=O)O)O)C(=O)O)O)O,reduction,O=C(O)CCC1=CC=C(O)C(O)=C1,O=C(O)CCC1=CC=CC(O)=C1,2006/11,Microbial metabolism of caffeic acid and its esters chlorogenic and caftaric acids by human faecal microbiota in vitro,10.1016/j.biopha.2006.07.084
TS0154,HGMMS,quercetin-3-rutinoside,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O)O)O)O)O)O,hydrolysis,C1=CC(=CC(=C1)O)CC(=O)O,C1=CC(=C(C=C1CC(=O)O)O)O,2003/06,Chlorogenic acid quercetin-3-rutinoside and black tea phenols are extensively metabolized in humans,10.1093/jn/133.6.1806
TS0155,HGMMS,daidzin,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,hydrolysis,O=C1C(C=CC(O)=C2)=C2OC=C1C3=CC=C(O)C=C3,NONE,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0156,HGMMS,genistin,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,hydrolysis,O=C1C2=C(O)C=C(O)C=C2OC=C1C3=CC=C(O)C=C3,NONE,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0157,HGMMS,formononetin,COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O,dealkylation,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O,NONE,2015/02,Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties,10.1155/2015/905215
TS0158,HGMMS,"3,5,7-TMF",O=C1C2=C(OC)C=C(OC)C=C2OC(C3=CC=CC=C3)=C1OC,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC=CC=C3)=C1OC)O)OC,O=C1C2=C(C=C(C=C2OC(C3=CC=CC=C3)=C1O)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0159,HGMMS,"5,7,4'-TMF",O=C1C2=C(OC)C=C(OC)C=C2OC(C3=CC=C(OC)C=C3)=C1,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC=C(C=C3)O)=C1)O)O,NONE,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0160,HGMMS,"3,5,7,4'-TMF",O=C1C2=C(OC)C=C(OC)C=C2OC(C3=CC=C(OC)C=C3)=C1OC,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC=C(C=C3)OC)=C1OC)O)OC,O=C1C2=C(C=C(C=C2OC(C3=CC=C(C=C3)O)=C1O)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0161,HGMMS,"5,7,3',4'-TMF",O=C1C2=C(OC)C=C(OC)C=C2OC(C3=CC(OC)=C(OC)C=C3)=C1,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC(OC)=C(C=C3)O)=C1)O)OC,O=C1C2=C(C=C(C=C2OC(C3=CC(O)=C(C=C3)O)=C1)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0162,HGMMS,"3,5,7,3',4'-PMF",O=C1C2=C(OC)C=C(OC)C=C2OC(C3=CC(OC)=C(OC)C=C3)=C1OC,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC(OC)=C(C=C3)OC)=C1OC)O)OC,O=C1C2=C(C=C(C=C2OC(C3=CC(O)=C(C=C3)O)=C1O)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0163,HGMMS,5-OH-7-MF,O=C1C2=C(O)C=C(OC)C=C2OC(C3=CC=CC=C3)=C1,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC=CC=C3)=C1)O)O,NONE,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0164,HGMMS,"5-OH-3,7-MF",O=C1C2=C(O)C=C(OC)C=C2OC(C3=CC=CC=C3)=C1OC,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC=CC=C3)=C1OC)O)O,O=C1C2=C(C=C(C=C2OC(C3=CC=CC=C3)=C1O)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0165,HGMMS,"5-OH-7,4'-DMF",O=C1C2=C(O)C=C(OC)C=C2OC(C3=CC=C(OC)C=C3)=C1,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC=C(C=C3)OC)=C1)O)O,O=C1C2=C(C=C(C=C2OC(C3=CC=C(C=C3)O)=C1)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0166,HGMMS,"5,3'-diOH-3,7,4'-TMF",O=C1C2=C(O)C=C(OC)C=C2OC(C3=CC(O)=C(OC)C=C3)=C1OC,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC(O)=C(C=C3)OC)=C1OC)O)O,O=C1C2=C(C=C(C=C2OC(C3=CC(O)=C(C=C3)O)=C1O)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0167,HGMMS,"5-OH-3,7,3',4'-TMF",O=C1C2=C(O)C=C(OC)C=C2OC(C3=CC(OC)=C(OC)C=C3)=C1OC,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC(O)=C(C=C3)OC)=C1OC)O)O,O=C1C2=C(C=C(C=C2OC(C3=CC(O)=C(C=C3)O)=C1O)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0168,HGMMS,syringic acid,COC1=CC(=CC(=C1O)OC)C(=O)O,dealkylation,OC1=CC(C(O)=O)=CC(O)=C1O,OC1=CC(C(O)=O)=CC(OC)=C1O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0169,HGMMS,vanillic acid,COC1=C(C=CC(=C1)C(=O)O)O,dealkylation,OC1=C(O)C=CC(C(O)=O)=C1,NONE,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
TS0170,HGMMS,Glycitein,COC1=C(C=C2C(=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O)O,reduction,COC1=C(O)C=C2C(C(C(CO2)C3=CC=C(O)C=C3)=O)=C1,COC1=C(O)C=C2C(CC(CO2)C3=CC=C(O)C=C3)=C1,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0171,HGMMS,Glycitin,COC1=C(C=C2C(=C1)C(=O)C(=CO2)C3=CC=C(C=C3)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O,"hydrolysis,  reduction",COC1=C(O)C=C2C(C(C(C3=CC=C(O)C=C3)=CO2)=O)=C1,COC1=C(O)C=C2C(C(C(CO2)C3=CC=C(O)C=C3)=O)=C1,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0172,HGMMS,Secoisolariciresinol,COC1=C(C=CC(=C1)C[C@@H](CO)[C@@H](CC2=CC(=C(C=C2)O)OC)CO)O,dealkylation,OC1=C(O)C=CC(C[C@H]([C@H](CO)CC2=CC(O)=C(O)C=C2)CO)=C1,NONE,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0173,HGMMS,Secoisolariciresinol diglucoside,COC1=C(C=CC(=C1)C[C@@H](CO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[C@@H](CC3=CC(=C(C=C3)O)OC)CO[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O,"hydrolysis, dealkylation",COC1=C(O)C=CC(C[C@H]([C@H](CO)CC2=CC(OC)=C(O)C=C2)CO)=C1,OC1=C(C=CC(C[C@@H](CO)[C@@H](CC2=CC(O)=C(C=C2)O)CO)=C1)O,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0174,HGMMS,Pinoresinol diglucoside,COC1=C(C=CC(=C1)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)OC)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O,"hydrolysis, dealkylation",COC1=C(O)C=CC([C@@H]2[C@H]3CO[C@H](C4=CC(OC)=C(O)C=C4)[C@H]3CO2)=C1,OC1=C(O)C=CC([C@@H]2[C@H]3CO[C@H](C4=CC(O)=C(O)C=C4)[C@H]3CO2)=C1,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0175,HGMMS,Pinoresinol,COC1=C(C=CC(=C1)[C@@H]2[C@H]3CO[C@@H]([C@H]3CO2)C4=CC(=C(C=C4)O)OC)O,dealkylation,OC1=C(O)C=CC([C@@H]2[C@H]3CO[C@H](C4=CC(O)=C(O)C=C4)[C@H]3CO2)=C1,NONE,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0176,HGMMS,Arctiin,COC1=C(C=C(C=C1)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)OC)OC,"hydrolysis, dealkylation",COC1=C(OC)C=C(C[C@H]2COC([C@@H]2CC3=CC(OC)=C(O)C=C3)=O)C=C1,OC1=C(O)C=C(C[C@H]2COC([C@@H]2CC3=CC(O)=C(O)C=C3)=O)C=C1,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0177,HGMMS,arctigenin,COC1=C(C=C(C=C1)C[C@H]2COC(=O)[C@@H]2CC3=CC(=C(C=C3)O)OC)OC,hydrolysis,OC1=C(O)C=C(C[C@H]2COC([C@@H]2CC3=CC(O)=C(O)C=C3)=O)C=C1,NONE,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0178,HGMMS,Ellagitannin,CC(=O)C[C@@]1(C(=O)C=C2[C@@H]3[C@]1(OC4=C3C(=CC(=C4O)O)C(=O)O[C@@H]5[C@H]6COC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O[C@@H]5[C@H]([C@@H](O6)OC(=O)C9=CC(=C(C(=C9)O)O)O)OC2=O)O)O)O)O)O)O)O)O,hydrolysis,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,NONE,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
TS0179,HGMMS,Curcumin,COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O,reduction,COC1=C(O)C=CC(CCC(CC(CCC2=CC(OC)=C(O)C=C2)=O)=O)=C1,NONE,2015/07,The degradation of curcuminoids in a human faecal fermentation model,10.3109/09637486.2015.1095865
TS0180,HGMMS,DMC,O=C(CC(/C=C/C1=CC(OC)=C(O)C=C1)=O)/C=C/C2=CC=C(O)C=C2,reduction,O=C(CCC1=CC=C(C=C1)O)CC(CCC2=CC(OC)=C(C=C2)O)=O,NONE,2015/07,The degradation of curcuminoids in a human faecal fermentation model,10.3109/09637486.2015.1095865
TS0181,HGMMS,Bis-DMC,O=C(CC(/C=C/C1=CC=C(O)C=C1)=O)/C=C/C2=CC=C(O)C=C2,reduction,O=C(CCC1=CC=C(C=C1)O)CC(CCC2=CC=C(C=C2)O)=O,NONE,2015/07,The degradation of curcuminoids in a human faecal fermentation model,10.3109/09637486.2015.1095865
TS0182,HGMMS,Quercetin-4'-o-glucoside,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)OC4C(C(C(C(O4)CO)O)O)O,hydrolysis,O=C(C1=C(O)C=C(O)C=C1O2)C(O)=C2C3=CC(O)=C(O)C=C3,NONE,2014/12,The microbial degradation of onion flavonol glucosides and their roasting products by the human gut bacteria Eubacterium ramulus and Flavonifractor plautii,10.1016/j.foodres.2014.11.051
TS0183,HGMMS,"Quercetin-3,4'-DI-O-glucoside",C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)OC4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)OC5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O,hydrolysis,O=C(C1=C(O)C=C(O)C=C1O2)C(O)=C2C3=CC(O)=C(O)C=C3,NONE,2014/12,The microbial degradation of onion flavonol glucosides and their roasting products by the human gut bacteria Eubacterium ramulus and Flavonifractor plautii,10.1016/j.foodres.2014.11.051
TS0184,HGMMS,Quercitrin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O,hydrolysis,OC1=C(C2=CC(O)=C(O)C=C2)OC3=CC(O)=CC(O)=C3C1=O,NONE,1987/12,Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans,10.1042/bj2480953
TS0185,HGMMS,Robinin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)O)O)O)C6=CC=C(C=C6)O)O)O)O)O)O)O,hydrolysis,OC1=C(C2=CC=C(O)C=C2)OC3=CC(O)=CC(O)=C3C1=O,NONE,1987/12,Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans,10.1042/bj2480953
TS0186,HGMMS,kaempferol,C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O,unknown,NONE,NONE,2007/04,Biotransformation of common bean (Phaseolus vulgaris L.) flavonoid glycosides by bifidobacterium species from human intestinal origin,10.1021/jf062997g
TS0187,HGMMS,Safflor Yellow B,C1=CC(=CC=C1/C=C/C(=C/2\C(=C(C(=O)C(C2=O)(C3C(C(C(C(O3)CO)O)O)O)O)C(C4=C(/C(=C(\C=C/C5=CC=C(C=C5)O)/O)/C(=O)C(C4=O)(C6C(C(C(C(O6)CO)O)O)O)O)O)C(C(C(C(CO)O)O)O)O)O)/O)O,hydrolysis,O=C(C(C1C(O)C(O)C(O)C(CO)O1)(O)C/2=O)/C(C(C2=C(O)/C=C/C3=CC=C(O)C=C3)=O)=C\C4=C(O)/C(C(C(C5C(O)C(O)C(O)C(CO)O5)(O)C4=O)=O)=C(O)\C=C/C6=CC=C(O)C=C6,NONE,1993/01,Metabolism of safflor yellow B by human intestinal bacteria,10.1021/np50091a006
TS0188,HGMMS,trans-resveratrol,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,"reduction, dehydroxylation",OC1=CC(CCC2=CC=C(O)C=C2)=CC(O)=C1,OC1=CC=CC(/C=C/C2=CC=C(O)C=C2)=C1,2013/01,In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota,10.3945/ajcn.112.049379
TS0189,HGMMS,oxyresveratrol,C1=CC(=C(C=C1O)O)/C=C/C2=CC(=CC(=C2)O)O,reduction,OC1=CC(O)=C(CCC2=CC(O)=CC(O)=C2)C=C1,NONE,2019/02,Metabolism of Stilbenoids by Human Faecal Microbiota,10.3390/molecules24061155
TS0190,HGMMS,thunalbene,COC1=CC(=CC(=C1)O)/C=C/C2=CC(=CC=C2)O,dealkylation,OC1=CC(/C=C/C2=CC(O)=CC=C2)=CC(O)=C1,NONE,2019/02,Metabolism of Stilbenoids by Human Faecal Microbiota,10.3390/molecules24061155
TS0191,HGMMS,Myricetin,C1=C(C=C(C(=C1O)O)O)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O,unknown,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O,NONE,2015/02,Bioavailability of dietary polyphenols and gut microbiota metabolism: antimicrobial properties,10.1155/2015/905215
TS0192,HGMMS,naringin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)O)O)CO)O)O)O)O)O,hydrolysis,OC1=CC(O)=C2C(C[C@@H](C3=CC=C(O)C=C3)OC2=C1)=O,NONE,2013/09,Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products,10.1016/j.freeradbiomed.2003.09.022
TS0193,HGMMS,Xanthohumol,CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)/C=C/C2=CC=C(C=C2)O)O)C,"reduction, dealkylation",C/C(C)=C\CC1=C(O)C(C(CCC2=CC=C(O)C=C2)=O)=C(OC)C=C1O,C/C(C)=C\CC1=C(O)C(C(CCC2=CC=C(O)C=C2)=O)=C(O)C=C1O,2020/01,Reductive Metabolism of Xanthohumol and 8-Prenylnaringenin by the Intestinal Bacterium Eubacterium ramulus,10.1002/mnfr.201800923
TS0194,HGMMS,8-Prenylnaringenin,CC(=CCC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=CC=C(C=C3)O)C,"reverse Michael addition, reduction",C/C(C)=C\CC1=C(O)C(C(/C=C/C2=CC=C(O)C=C2)=O)=C(O)C=C1O,C/C(C)=C\CC1=C(O)C(C(CCC2=CC=C(O)C=C2)=O)=C(O)C=C1O,2020/01,Reductive Metabolism of Xanthohumol and 8-Prenylnaringenin by the Intestinal Bacterium Eubacterium ramulus,10.1002/mnfr.201800923
TS0195,HGMMS,Desmethylxanthohumol,CC(=CCC1=C(C(=C(C=C1O)O)C(=O)/C=C/C2=CC=C(C=C2)O)O)C,reduction,C/C(C)=C\CC1=C(O)C(C(CCC2=CC=C(O)C=C2)=O)=C(O)C=C1O,NONE,2020/01,Reductive Metabolism of Xanthohumol and 8-Prenylnaringenin by the Intestinal Bacterium Eubacterium ramulus,10.1002/mnfr.201800923
TS0196,HGMMS,Hesperidin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,hydrolysis,COC1=C(O)C=C([C@@H]2CC(C3=C(O)C=C(O)C=C3O2)=O)C=C1,NONE,2006/02,Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized double-blind crossover trial,10.1093/jn/136.2.404
TS0197,HGMMS,Isoflavone,C1=CC=C(C=C1)C2=COC3=CC=CC=C3C2=O,reduction,O=C1[C@H](C2=CC=CC=C2)COC3=C1C=CC=C3,NONE,2011/08,Stereospecific microbial production of isoflavanones from isoflavones and isoflavone glucosides,10.1007/s00253-011-3310-7
TS0198,HGMMS,7-Hydroxyisoflavone,C1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O,reduction,OC1=CC2=C(C=C1)C([C@H](C3=CC=CC=C3)CO2)=O,NONE,2011/08,Stereospecific microbial production of isoflavanones from isoflavones and isoflavone glucosides,10.1007/s00253-011-3310-7
TS0199,HGMMS,Deleobuvir,CN1C2=C(C=CC(=C2)C(=O)NC3(CCC3)C4=NC5=C(N4C)C=C(C=C5)/C=C/C(=O)O)C(=C1C6=NC=C(C=N6)Br)C7CCCC7,reduction,CN1C2=C(C(C3CCCC3)=C1C4=NC=C(Br)C=N4)C=CC(C(NC5(C6=NC7=C(C=C(CCC(O)=O)C=C7)N6C)CCC5)=O)=C2,NONE,2015/10,Defining the Role of Gut Bacteria in the Metabolism of Deleobuvir: In Vitro and In Vivo Studies,10.1124/dmd.115.064477
TS0200,HGMMS,7-deoxydoxorubicinolone,COC1=CC=CC2=C1C(C3=C(O)C4=C(C(O)=C3C2=O)C[C@](C(CO)=O)(O)CC4)=O,reduction,COC1=CC=CC2=C1C(=O)C3=C(C4=C(CC(CC4)(C(CO)O)O)C(=C3C2=O)O)O,NONE,2017/11,Transformation of the Anticancer Drug Doxorubicin in the Human Gut Microbiome,10.1021/acsinfecdis.7b00166
TS0201,HGMMS,Doxorubicin,C[C@H]1[C@@H](O)[C@@H](N)C[C@H](O[C@H]2C[C@@](C(CO)=O)(O)CC3=C2C(O)=C4C(C(C5=C(C(OC)=CC=C5)C4=O)=O)=C3O)O1,"hydrolysis, reduction",COC1=CC=CC2=C1C(C3=C(C4=C(C[C@](O)(CC4)C(CO)=O)C(O)=C3C2=O)O)=O,COC1=CC=CC2=C1C(=O)C3=C(C4=C(CC(CC4)(C(CO)O)O)C(=C3C2=O)O)O,2017/11,Transformation of the Anticancer Drug Doxorubicin in the Human Gut Microbiome,10.1021/acsinfecdis.7b00166
TS0202,HGMMS,Prunasin,N#C[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C2=CC=CC=C2,hydrolysis,N#CC(O)C1=CC=CC=C1,NONE,2010/06,Metabolites of amygdalin under simulated human digestive fluids,10.3109/09637481003796314
TS0203,HGMMS,TNT,CC1=C(C=C(C=C1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-],reduction,CC1=C([N+]([O-])=O)C=C(N)C=C1N,CC1=C(N)C=C(N)C=C1N,1997/02,246-Trinitrotoluene (TNT) transformation by clostridia isolated from a munition-fed bioreactor: comparison with non-adapted bacteria,10.1038/sj.jim.2900257
TS0204,HGMMS,"2,3-DNT",CC1=C(C(=CC=C1)[N+](=O)[O-])[N+](=O)[O-],reduction,CC1=C([N+]([O-])=O)C(N)=CC=C1,CC1=C(N)C([N+]([O-])=O)=CC=C1,1984/10,Metabolism of dinitrotoluene isomers by Escherichia coli isolated from human intestine,10.1248/cpb.32.4070
TS0205,HGMMS,"2,4-DNT",CC1=C(C=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],reduction,CC1=C(N)C=C([N+]([O-])=O)C=C1,CC1=C([N+]([O-])=O)C=C(N)C=C1,1984/10,Metabolism of dinitrotoluene isomers by Escherichia coli isolated from human intestine,10.1248/cpb.32.4070
TS0206,HGMMS,"3,4-DNT",CC1=CC(=C(C=C1)[N+](=O)[O-])[N+](=O)[O-],reduction,CC1=CC([N+]([O-])=O)=C(N)C=C1,CC1=CC(N)=C([N+]([O-])=O)C=C1,1984/10,Metabolism of dinitrotoluene isomers by Escherichia coli isolated from human intestine,10.1248/cpb.32.4070
TS0207,HGMMS,1-Nitropyrene,C1=CC2=C3C(=C1)C=CC4=C(C=CC(=C43)C=C2)[N+](=O)[O-],reduction,NC1=C2C=CC3=CC=CC4=C3C2=C(C=C4)C=C1,NONE,1983/07,The role of intestinal microflora in the metabolic reduction of 1-nitropyrene to 1-aminopyrene in conventional and germfree rats and in humans,10.1016/0304-3835(83)90100-3
TS0208,HGMMS,6-Nitrobenzo[a]pyrene,C1=CC=C2C(=C1)C3=C4C(=C2[N+](=O)[O-])C=CC5=CC=CC(=C54)C=C3,reduction,NC1=C2C=CC3=CC=CC4=CC=C(C2=C34)C5=CC=CC=C51,O=NC1=C2C=CC3=CC=CC4=CC=C(C2=C34)C5=CC=CC=C51,1988/11,Nitroreduction of 6-nitrobenzo[a]pyrene: a potential activation pathway in humans,10.1016/0165-7992(88)90028-0
TS0209,HGMMS,2-nitrofluorene,C1C2=CC=CC=C2C3=C1C=C(C=C3)[N+](=O)[O-],unknown,NONE,NONE,2000/11,Effects of human intestinal flora on mutagenicity of and DNA adduct formation from food and environmental mutagens,10.1093/carcin/21.11.2105
TS0210,HGMMS,Balsalazide,C1=CC(=CC=C1C(=O)NCCC(=O)[O])N=NC2=CC(=C(C=C2)[O])C(=O)O,reduction,OC1=CC=C(N)C=C1C(O)=O,NONE,1983/07,Studies of two novel sulfasalazine analogs ipsalazide and balsalazide,10.1007/BF01299921
TS0211,HGMMS,Ipsalazide,C1=CC(=CC=C1C(=O)NCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,reduction,OC1=CC=C(N)C=C1C(O)=O,NONE,1983/07,Studies of two novel sulfasalazine analogs ipsalazide and balsalazide,10.1007/BF01299921
TS0212,HGMMS,Glyceryl trinitrate,C(C(CO[N+](=O)[O-])O[N+](=O)[O-])O[N+](=O)[O-],hydrolysis,OC(CO[N+]([O-])=O)CO[N+]([O-])=O,OCC(O)CO[N+]([O-])=O,1993/08,The role of the gastrointestinal microflora in the metabolism of drugs,10.1016/0378-5173(93)90121-U
TS0213,HGMMS,Isosorbide Dinitrate,C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O[N+](=O)[O-])O[N+](=O)[O-],hydrolysis,[H][C@]12OC[C@H](O[N+]([O-])=O)[C@]1(OC[C@H]2O)[H],NONE,1993/08,The role of the gastrointestinal microflora in the metabolism of drugs,10.1016/0378-5173(93)90121-U
TS0214,HGMMS,sennoside A,C1=CC2=C(C(=C1)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(=O)C4=C([C@@H]2[C@@H]5C6=C(C(=CC=C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C(=O)C8=C5C=C(C=C8O)C(=O)O)C=C(C=C4O)C(=O)O,hydrolysis,OC1=CC=CC2=C1C(C3=C(C=C(C(O)=O)C=C3O)[C@@H]2[C@@H]4C5=C(C(C6=C4C=C(C(O)=O)C=C6O)=O)C(O)=CC=C5)=O,NONE,1980/11,Metabolism of sennosides by human intestinal bacteria,10.1159/000138437
TS0215,HGMMS,8-glucosyl-rhein anthrone,O=C(O)c4cc(O)c3C(=O)c1c(cccc1O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)Cc3c4,hydrolysis,O=C(c1cc2c(C(c3c(O)cccc3C2)=O)c(O)c1)O,NONE,1980/11,Metabolism of sennosides by human intestinal bacteria,10.1159/000138437
TS0216,HGMMS,methamphetamine,C[C@@H](CC1=CC=CC=C1)NC,dealkylation,C[C@H](N)CC1=CC=CC=C1,NONE,1973/05,The demethylation of methamphetamine by intestinal microflora,10.1111/j.2042-7158.1973.tb10043.x
TS0217,HGMMS,Budesonide,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,unknown,NONE,NONE,2013/11,Colonic bacterial metabolism of corticosteroids,10.1016/j.ijpharm.2013.09.007
TS0218,HGMMS,Beclometasone dipropionate,CCC(=O)OCC(=O)[C@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)Cl)O)C)C)OC(=O)CC,unknown,NONE,NONE,2013/11,Colonic bacterial metabolism of corticosteroids,10.1016/j.ijpharm.2013.09.007
TS0219,HGMMS,Urolithin M-6,OC1=C(O)C(O)=C(C2=C(OC3=O)C=C(O)C=C2)C3=C1,dehydroxylation,OC1=C(O)C=C(C2=C(OC3=O)C=C(O)C=C2)C3=C1,NONE,2014/08,Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species,10.1039/c4fo00092g
TS0220,HGMMS,mercaptopurine,C1=NC2=C(N1)C(=S)N=CN2,unknown,NONE,NONE,2016/09,Microbial metabolism of thiopurines: A method to measure thioguanine nucleotides,10.1016/j.mimet.2016.07.017
TS0221,HGMMS,5-aminosalicylate,C1=CC(=C(C=C1N)C(=O)O)O,acetylation ,O=C(O)C1=C(O)C=CC(NC(C)=O)=C1,NONE,1987/11,Role of the intestinal flora in the acetylation of sulfasalazine metabolites,10.1016/0006-2952(87)90034-7
TS0222,HGMMS,Sulfapyridine,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N,acetylation ,O=S(NC1=CC=CC=N1)(C2=CC=C(NC(C)=O)C=C2)=O,NONE,1987/11,Role of the intestinal flora in the acetylation of sulfasalazine metabolites,10.1016/0006-2952(87)90034-7
TS0223,HGMMS,Acetaminophen sulfate,CC(=O)NC1=CC=C(C=C1)OS(=O)(=O)O,unknown,NONE,NONE,2019/01,I-Screen: an ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent,TNO: 871815
TS0224,HGMMS,Mycophenolic Acid Glucuronide,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C(=O)O)O)O)O,unknown,NONE,NONE,2019/01,I-Screen: an ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent,TNO: 871815
TS0225,HGMMS,Benzydamine N-oxide,C[N+](C)(CCCOC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3)[O-],unknown,NONE,NONE,2019/01,I-Screen: an ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent,TNO: 871815
TS0226,HGMMS,Imipramine N-Oxide,C[N+](C)(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)[O-],unknown,NONE,NONE,2019/01,I-Screen: an ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent,TNO: 871815
TS0227,HGMMS,SN-38 Glucuronide,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O,unknown,NONE,NONE,2019/01,I-Screen: an ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent,TNO: 871815
TS0228,HGMMS,Raloxifene 6-Glucuronide,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)C(=O)O)O)O)O)C6=CC=C(C=C6)O,unknown,NONE,NONE,2019/01,I-Screen: an ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent,TNO: 871815
TS0229,HGMMS,Azetirelin,C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CC(=O)N3)C(=O)N,unknown,NONE,NONE,1997/08,Metabolism of azetirelin a new thyrotropin-releasing hormone (TRH) analogue by intestinal microorganisms,10.1023/a:1012141025938
TS0230,HGMMS,4-Nitrobenzoic acid,[2H]C1=C(C(=C(C(=C1C(=O)O)[2H])[2H])[N+](=O)[O-])[2H],reduction,O=C(O)C1=CC=C(N)C=C1,NONE,1972/03,Metabolism of azetirelin a new thyrotropin-releasing hormone (TRH) analogue by intestinal microorganisms,10.1111/j.1600-0773.1972.tb03610.x
TS0231,HGMMS,3-Hydroxycinnamic acid,C1=CC(=CC(=C1)O)/C=C/C(=O)O,reduction,OC1=CC=CC(CCC(O)=O)=C1,NONE,1972/03,Metabolism of azetirelin a new thyrotropin-releasing hormone (TRH) analogue by intestinal microorganisms,10.1111/j.1600-0773.1972.tb03610.x
TS0232,HGMMS,Acid yellow,CC1=C(C(=O)N(N1)C2=CC=C(C=C2)S(=O)(=O)O)N=NC3=CC=CC=C3,unknown,NONE,NONE,1972/03,Metabolism of azetirelin a new thyrotropin-releasing hormone (TRH) analogue by intestinal microorganisms,10.1111/j.1600-0773.1972.tb03610.x
TS0233,HGMMS,N-Nitrosodiphenylamine,C1=CC=C(C=C1)N(C2=CC=CC=C2)N=O,reduction,C1(NC2=CC=CC=C2)=CC=CC=C1,NONE,1975/01,Degradation of N-nitrosamines by intestinal bacteria,10.1128/am.29.1.7-12.1975
TS0234,HGMMS,N-nitrosopyrrolidine,C1CCN(C1)N=O,reduction,C1CCNC1,NONE,1975/01,Degradation of N-nitrosamines by intestinal bacteria,10.1128/am.29.1.7-12.1975
TS0235,HGMMS,N-Nitrosodimethylamine,CN(C)N=O,reduction,CNC,NONE,1975/01,Degradation of N-nitrosamines by intestinal bacteria,10.1128/am.29.1.7-12.1975
TS0236,HGMMS,chloromycetin derivative-1,OC[C@@H](NC(CCl)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0237,HGMMS,chloromycetin derivative-2,OC[C@@H](NC(C(Cl)(Cl)Cl)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0238,HGMMS,chloromycetin derivative-3,OC[C@@H](NC(C(C)(C)C)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0239,HGMMS,chloromycetin derivative-4,OC[C@@H](NC(CI)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0240,HGMMS,chloromycetin derivative-5,OC[C@@H](NC(C(Br)Br)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0241,HGMMS,chloromycetin derivative-6,OC[C@@H](NC(C(C)C)=O)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0242,HGMMS,chloromycetin derivative-7,O=C(C(Cl)Cl)NC[C@H](O)C1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0243,HGMMS,chloromycetin derivative-8,C[C@@H](NC(C(Cl)Cl)=O)CC1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0244,HGMMS,chloromycetin derivative-9,CC[C@H](C1=CC=C([N+]([O-])=O)C=C1)NC(C(Cl)Cl)=O,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0245,HGMMS,chloromycetin derivative-10,C[C@H](C1=CC=C([N+]([O-])=O)C=C1)NC(C(Cl)Cl)=O,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0246,HGMMS,chloromycetin derivative-11,O=C(C(Cl)Cl)NCC1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0247,HGMMS,chloromycetin derivative-12,O=C(C(Cl)Cl)NC1=CC=C([N+]([O-])=O)C=C1,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0248,HGMMS,chloromycetin derivative-13,O=C(N[C@@H]([C@@H](C1=CC=C(C=C1)[N+]([O-])=O)OC(C)=O)COC(C)=O)C(Cl)Cl,unknown,NONE,NONE,1953/03,Reduction of chloromycetin and related compounds by Escherichia coli,10.1128/jb.65.3.313-317.1953
TS0249,HGMMS,cholestenone,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,reduction,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@H]4[C@@]3(CC[C@@H](C4)O)C)C,NONE,2020/08,Cholesterol Metabolism by Uncultured Human Gut Bacteria Influences Host Cholesterol Level,10.1016/j.chom.2020.05.013
TS0250,HGMMS,Puerarin,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,unknown,NONE,NONE,2015/10,Gut Microbiota-Mediated Drug-Antibiotic Interactions,10.1124/dmd.115.063867
TS0251,HGMMS,cyclamate,C1CCC(CC1)NS(=O)(=O)O,hydrolysis,NC1CCCCC1,NONE,1972/10,The role of the gut flora in the metabolism of cyclamate,10.1042/bj1290881
TS0252,HGMMS,amygdalin,C1=CC=C(C=C1)C(C#N)OC2C(C(C(C(O2)COC3C(C(C(C(O3)CO)O)O)O)O)O)O,hydrolysis,N#C[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C2=CC=CC=C2,N#CC(O)C1=CC=CC=C1,2010/06,Metabolites of amygdalin under simulated human digestive fluids,10.3109/09637481003796314
TS0253,HGMMS,Wogonoside,COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)OC4C(C(C(C(O4)C(=O)O)O)O)O,hydrolysis,COC1=C(O)C=C(O)C2=C1OC(C3=CC=CC=C3)=CC2=O,NONE,2015/10,Metabolism of Wogonoside by Human Fecal Microflora and Its Anti-pruritic Effect,10.4062/biomolther.2009.17.2.211
TS0254,HGMMS,Baicalin,C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O,hydrolysis,O=C(C1=C(O)C(O)=C(O)C=C1O2)C=C2C3=CC=CC=C3,NONE,1998/02,Intestinal bacterial metabolism of flavonoids and its relation to some biological activities,10.1007/BF03216747
TS0255,HGMMS,Poncirin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC=C(C=C5)OC)O)CO)O)O)O)O)O,hydrolysis,OC1=CC(O)=C2C(C[C@@H](C3=CC=C(OC)C=C3)OC2=C1)=O,NONE,1998/02,Intestinal bacterial metabolism of flavonoids and its relation to some biological activities,10.1007/BF03216747
TS0256,HGMMS,Diosmin,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=C3)OC(=CC4=O)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O,hydrolysis,OC1=CC(O)=C2C(OC(C3=CC(O)=C(OC)C=C3)=CC2=O)=C1,NONE,1998/02,Intestinal bacterial metabolism of flavonoids and its relation to some biological activities,10.1007/BF03216747
TS0257,HGMMS,5-fluorouracil,C1=C(C(=O)NC(=O)N1)F,reduction,C1C(C(=O)NC(=O)N1)F,NONE,2018/04,The Metabolism of Fluoropyrimidine Anticancer Drugs by the Human Gut Microbiome,10.1096/fasebj.2018.32.1_supplement.534.22
TS0258,HGMMS,flunitrazepam,CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3F,reduction,CN1C(CN=C(C2=CC=CC=C2F)C3=C1C=CC(N)=C3)=O,NONE,2009/07,Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines,10.1016/j.bcp.2009.03.019
TS0259,HGMMS,nitrazepam,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3,reduction,O=C1CN=C(C2=CC=CC=C2)C(C=C(N)C=C3)=C3N1,NONE,2009/07,Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines,10.1016/j.bcp.2009.03.019
TS0260,HGMMS,Shikonin,CC(=CC[C@H](C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C,unknown,C/C(C)=C\CCC1=CC(C2=C(O)C=CC(O)=C2C1=O)=O,NONE,1994/03,Biotransformation of shikonin by human intestinal bacteria,10.1016/S0040-4020(01)81108-X
TS0261,HGMMS,MDPM,O=S(OC(C=C1)=CC=C1C(C2=CC=C(O)C=C2)C3=CC=CC=N3)(O)=O,hydrolysis,OC(C=C1)=CC=C1C(C2=CC=C(O)C=C2)C3=CC=CC=N3,NONE,1992/05,The role of intestinal bacteria in the transformation of sodium picosulfate,10.1254/jjp.59.1
TS0262,HGMMS,Picosulfuric acid,C1=CC=NC(=C1)C(C2=CC=C(C=C2)OS(=O)(=O)O)C3=CC=C(C=C3)OS(=O)(=O)O,hydrolysis,O=S(OC(C=C1)=CC=C1C(C2=CC=C(O)C=C2)C3=CC=CC=N3)(O)=O,OC(C=C1)=CC=C1C(C2=CC=C(O)C=C2)C3=CC=CC=N3,1992/05,The role of intestinal bacteria in the transformation of sodium picosulfate,10.1254/jjp.59.1
TS0263,HGMMS,Phorbol,C[C@@H]1[C@H]([C@@]2([C@@H](C2(C)C)[C@H]3[C@]1([C@@H]4C=C(C(=O)[C@]4(CC(=C3)CO)O)C)O)O)O,unknown,C[C@@H]1CC(C[C@H]2[C@@]1(O)[C@@H]3C=C(C)C([C@@]3(O)CC(CO)=C2)=O)=O,C[C@@H]1CC([C@@H](C(C)=C)[C@H]2[C@@]1(O)[C@@H]3C=C(C)C([C@@]3(O)CC(CO)=C2)=O)=O,2002/02,Biotransformation of phorbol by human intestinal bacteria,10.1248/cpb.50.160
TS0264,HGMMS,Pentobarbital,CCC1(C2=CC=CC=C2)C(NC(NC1=O)=O)=O,hydrolysis,O=C(N)C(CC)C1=CC=CC=C1,NONE,2006/01,The metabolism of phenobarbital a drug used for epilepsy by intestinal flora Bifidobacterium adolescentis and Bifidobacterium bifidum,10.1080/08910600600726979
TS0265,HGMMS,Pedunculagin,C1[C@@H]2[C@H]([C@H]3[C@H](C(O2)O)OC(=O)C4=CC(=C(C(=C4C5=C(C(=C(C=C5C(=O)O3)O)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6C7=C(C(=C(C=C7C(=O)O1)O)O)O)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
TS0266,HGMMS,coriariin B,C1C2C(C(C(C(O2)OC(=O)C3=CC(=C(C(=C3)OC4=C(C(=C(C=C4C(=O)O)O)O)O)O)O)OC(=O)C5=CC(=C(C(=C5)O)O)O)OC(=O)C6=CC(=C(C(=C6)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
TS0267,HGMMS,vescalagin,C1C2C(C3C4C(C5=C(C(=C(C(=C5C(=O)O4)C6=C(C(=C(C(=C6C(=O)O3)C7=C(C(=C(C=C7C(=O)O2)O)O)O)O)O)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
TS0268,HGMMS,stachyurin,C1C(C(OC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)O1)O)O)O)O)O)O)C4C5C(C6=C(C(=C(C(=C6C(=O)O5)C7=C(C(=C(C=C7C(=O)O4)O)O)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
TS0269,HGMMS,stenophyllanin A,C1[C@H]([C@@H](OC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)O1)O)O)O)O)O)O)C4[C@@H]5[C@@H](C6=C(C(=C(C(=C6C(=O)O5)C7=C(C(=C(C=C7C(=O)O4)O)O)O)O)O)O)C8=C(C=C(C9=C8OC(C(C9)O)C1=CC(=C(C=C1)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
TS0270,HGMMS,salicarinin A,C1CC(=O)C2=CC(=C(C(=C2C3=C(C(=C(C=C3C(=O)CC4C1CC(=O)C5=CC(=C(C(=C5C6=C7C(=C(C(=C6O)O)O)C8=C9C(=C(C(=C8O)O)O)C(C(C4OC7=O)OC9=O)O)O)O)O)OC1=C(C(=C(C=C1C(=O)OC1COC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)OC1C1CCC2=CC(=C(C(=C2C2=C3C(=C(C(=C2O)O)O)C(C1OC3=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
TS0271,HGMMS,agrimoniin,C1[C@@H]2[C@H]([C@H]3[C@H]([C@H](O2)OC(=O)C4=CC(=C(C(=C4)OC5=C(C(=C(C=C5C(=O)O[C@@H]6[C@H]7[C@H]([C@H]8[C@H](O6)COC(=O)C9=CC(=C(C(=C9C2=C(C(=C(C=C2C(=O)O8)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O7)O)O)O)O)O)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O3)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O1)O)O)O)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
TS0272,HGMMS,oenothein B,C1[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)O)OC(=O)C3=CC(=C(C(=C3OC4=C(C(=C5C(=C4)C(=O)OC[C@@H]6[C@@H]([C@H]([C@H]([C@@H](O6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)O)O)O)OC(=O)C9=CC(=C(C(=C95)O)O)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O1)O)O)O)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
TS0273,HGMMS,Epacadostat,C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F,dehydroxylation,O=S(NCCNC1=NON=C1C(N)=NC2=CC(Br)=C(F)C=C2)(N)=O,NONE,2017/11,Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs,10.1007/s12272-017-0986-y
TS0274,HGMMS,Glycyrrhizin,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O,hydrolysis,C[C@]12CC[C@](C)(C(O)=O)C[C@H]1C3=CC([C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC2)=O,NONE,1994/02,Intestinal bacterial hydrolysis is indispensable to absorption of 18 beta-glycyrrhetic acid after oral administration of glycyrrhizin in rats,10.1111/j.2042-7158.1994.tb03756.x
TS0275,HGMMS,ginsenoside Rb2,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@H](CO8)O)O)O)O)O)O)C,hydrolysis,C/C(C)=C\CC[C@@]([C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]3[C@@]2(C)CC[C@@H]4[C@]3(C)CC[C@H](O)C4(C)C)(O)C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
TS0276,HGMMS,ginsenoside Rc,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H](O8)CO)O)O)O)O)O)C,hydrolysis,C/C(C)=C\CC[C@@]([C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]3[C@@]2(C)CC[C@@H]4[C@]3(C)CC[C@H](O)C4(C)C)(O)C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
TS0277,HGMMS,ginsenoside Rg3,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O)C,hydrolysis,C/C(C)=C\CC[C@@]([C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]3[C@@]2(C)CC[C@@H]4[C@]3(C)CC[C@H](O)C4(C)C)(O)C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
TS0278,HGMMS,ginsenoside Rk1,CC(=CCCC(=C)[C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)C,hydrolysis,C/C(C)=C\CCC([C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]3[C@@]2(C)CC[C@@H]4[C@]3(C)CC[C@H](O)C4(C)C)=C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
TS0279,HGMMS,ginsenoside Re,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3C[C@@]4([C@H](C[C@H]([C@H]5[C@]4(CC[C@@H]5[C@](C)(CCC=C(C)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)[C@@]7([C@@H]3C([C@H](CC7)O)(C)C)C)C)CO)O)O)O)O)O,hydrolysis,O[C@H]1C[C@]2(C)[C@@H]([C@]3(C)[C@@H]1C(C)(C)[C@@H](O)CC3)C[C@@H](O)[C@H]4[C@@]2(C)CC[C@@H]4[C@](CC/C=C(C)\C)(O)C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
TS0280,HGMMS,ginsenoside Rg1,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)O)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C,hydrolysis,C/C(C)=C\CC[C@@]([C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]3[C@@]2(C)C[C@H](O)[C@@H]4[C@]3(C)CC[C@H](O)C4(C)C)(O)C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
TS0281,HGMMS,majonoside R2,C[C@]1(CC[C@H](O1)C(C)(C)O)[C@H]2CC[C@@]3([C@@H]2[C@@H](C[C@H]4[C@]3(C[C@@H]([C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O[C@H]7[C@@H]([C@H]([C@@H](CO7)O)O)O)C)O)C,hydrolysis,C[C@@]1([C@H]2CC[C@]3(C)[C@@H]2[C@H](O)C[C@H]4[C@@]3(C)C[C@H](O)[C@@H]5[C@]4(C)CC[C@H](O)C5(C)C)CC[C@@H](C(C)(O)C)O1,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
TS0282,HGMMS,ginsenoside Rf,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)O)C)O)C,hydrolysis,C/C(C)=C\CC[C@@]([C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]3[C@@]2(C)C[C@H](O)[C@@H]4[C@]3(C)CC[C@H](O)C4(C)C)(O)C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
TS0283,HGMMS,Genistein,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,reduction,OC1=C(C2)C(OCC2C3=CC=C(O)C=C3)=CC(O)=C1,NONE,2015/11,The influence of gut microbiota on drug metabolism and toxicity,10.1517/17425255.2016.1121234
TS0284,HGMMS,gemcitabine,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F,unknown,NONE,NONE,2017/06,Chemical transformation of xenobiotics by the human gut microbiota,10.1126/science.aag2770
TS0285,HGMMS,fludarabine,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N,unknown,NONE,NONE,2017/06,Chemical transformation of xenobiotics by the human gut microbiota,10.1126/science.aag2770
TS0286,HGMMS,CB1954,C1CN1C2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-],unknown,NONE,NONE,2017/06,Chemical transformation of xenobiotics by the human gut microbiota,10.1126/science.aag2770
TS0287,HGMMS,Fostamatinib,CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)(O)O)C,hydrolysis,CC1(C)C(NC2=C(C=CC(NC3=NC(NC4=CC(OC)=C(OC)C(OC)=C4)=NC=C3F)=N2)O1)=O,NONE,2010/07,Metabolism of fostamatinib the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation,10.1124/dmd.110.032151
TS0288,HGMMS,Trifluridine,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O,hydrolysis,O=C(N1)C(C(F)(F)F)=CNC1=O,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TS0289,HGMMS,Luteic acid,C1=C2C(=C(C(=C1O)O)O)C3=C(C(=C(C=C3C(=O)O)O)O)OC2=O,decarboxylation,OC1=C(O)C(O)=C(C2=C(OC3=O)C(O)=C(O)C=C2)C3=C1,NONE,2014/08,Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species,10.1039/c4fo00092g
TS0290,HGMMS,Eltrombopag,CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C,reduction,NC1=CC=CC(C2=CC(C(O)=O)=CC=C2)=C1O,NONE,2011/09,Investigations of hydrazine cleavage of eltrombopag in humans,10.1124/dmd.111.040188
TS0291,HGMMS,Ellagic acid,C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O,hydrolysis,OC1=C(O)C(O)=C(C2=C(OC3=O)C(O)=C(O)C=C2C(O)=O)C3=C1,NONE,2014/08,Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species,10.1039/c4fo00092g
TS0292,HGMMS,Choline,C[N+](C)(C)CCO,dealkylation,CN(C)C,NONE,2012/12,Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme,10.1073/pnas.1215689109
TS0293,HGMMS,Bromazepam,C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=N3,hydrolysis,NC1=C(C(C2=CC=CC=N2)=O)C=C(Br)C=C1,NONE,1987/10,Degradation of bromazepam by the intestinal microflora,10.1248/cpb.35.4338
TS0294,HGMMS,7-Bpdbd,C1C(=O)NC2=C(C=C(C=C2)Br)C(=N1)C3=CC=CC=C3,hydrolysis,NC1=C(C(C2=CC=CC=C2)=O)C=C(Br)C=C1,NONE,1987/10,Degradation of bromazepam by the intestinal microflora,10.1248/cpb.35.4338
TS0295,HGMMS,amiodarone,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,dealkylation,CCCCC1=C(C(C2=CC(I)=C(OCCNCC)C(I)=C2)=O)C3=CC=CC=C3O1,NONE,2018/08,Gut microbiota modulates drug pharmacokinetics,10.1080/03602532.2018.1497647
TS0296,HGMMS,BILR 355,CCN1C2=C(C=CC=N2)N(C(=O)C3=C1N=CC(=C3)CCOC4=CC=[N+](C5=CC=CC=C54)[O-])C,reduction,CCN1C2=C(N(C)C(C3=C1N=CC(CCOC4=CC=NC5=CC=CC=C54)=C3)=O)C=CC=N2,NONE,2012/06,Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase,10.1124/dmd.111.044362
TI0297,HGMMI,felbamate,c1ccc(cc1)C(COC(=O)N)COC(=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0298,HGMMI,cyclosporine a,CC[C@@H]1C(=O)N(CC(=O)N([C@@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N([C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@@H](C)C/C=C\C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0299,HGMMI,donepezil.hcl,COc1c(cc2c(c1)C[C@H](C2=O)CC1CCN(CC1)Cc1ccccc1)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0300,HGMMI,lincomycin.hcl,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@H]([C@@H]1[C@@H]([C@@H]([C@H]([C@H](O1)SC)O)O)O)[C@H](C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0301,HGMMI,mycophenolic acid,Cc1c(c(c(c2c1COC2=O)O)C/C=C(\C)/CCC(=O)O)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0302,HGMMI,tolbutamide,CCCCNC(=O)NS(=O)(=O)c1ccc(cc1)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0303,HGMMI,quinine,COc1cc2c(ccnc2cc1)[C@@H]([C@@H]1C[C@H]2CCN1C[C@H]2C=C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0304,HGMMI,propafenone.hcl,CCNC[C@H](COc1ccccc1C(=O)CCc1ccccc1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0305,HGMMI,flecainide acetate,C1CCN[C@H](C1)CNC(=O)c1c(ccc(c1)OCC(F)(F)F)OCC(F)(F)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0306,HGMMI,rosiglitazone,CN(CCOc1ccc(cc1)C[C@H]1C(=O)NC(=O)S1)c1ccccn1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0307,HGMMI,guanabenz acetate,c1cc(c(c(c1)Cl)/C=N\N=C(N)N)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0308,HGMMI,emtricitabine,C1[C@H](O[C@H](S1)CO)n1cc(c(nc1=O)N)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0309,HGMMI,caffeine,Cn1cnc2c1c(=O)n(c(=O)n2C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0310,HGMMI,maprotiline.hcl,CNCCC[C@]12CC[C@H](c3ccccc13)c1ccccc21,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0311,HGMMI,pilocarpine.hcl,CC[C@H]1[C@H](COC1=O)Cc1cncn1C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0312,HGMMI,haloperidol,C1CN(CCC1(c1ccc(cc1)Cl)O)CCCC(=O)c1ccc(cc1)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0313,HGMMI,naltrexone.hcl,C1CC1CN1CC[C@@]23[C@H]4C(=O)CC[C@@]2([C@@H]1Cc1c3c(c(cc1)O)O4)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0314,HGMMI,zolmitriptan,CN(C)CCc1c[nH]c2c1cc(cc2)C[C@@H]1COC(=O)N1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0315,HGMMI,aminophylline,Cn1c2c(c(=O)n(c1=O)C)[nH]cn2,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0316,HGMMI,apomorphine,CN1CCc2cccc3c2[C@@H]1Cc1c3c(c(cc1)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0317,HGMMI,promethazine,C[C@H](CN1c2ccccc2Sc2ccccc12)N(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0318,HGMMI,quetiapine,C1CN(CCN1CCOCCO)C1=Nc2ccccc2Sc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0319,HGMMI,amoxapine,C1CN(CCN1)C1=Nc2ccccc2Oc2c1cc(cc2)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0320,HGMMI,metoclopramide,CCN(CC)CCNC(=O)c1cc(c(cc1OC)N)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0321,HGMMI,famotidine,c1c(nc(s1)N=C(N)N)CSCC/C(=N\S(=O)(=O)N)/N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0322,HGMMI,ticlopidine,C1CN(Cc2c1scc2)Cc1ccccc1Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0323,HGMMI,vardenafil,CCCc1nc(c2n1[nH]c(nc2=O)c1c(ccc(c1)S(=O)(=O)N1CCN(CC1)CC)OCC)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0324,HGMMI,linezolid,CC(=O)NC[C@H]1CN(C(=O)O1)c1cc(c(cc1)N1CCOCC1)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0325,HGMMI,olopatadine,CN(C)CC/C=C\1/c2ccccc2COc2c1cc(cc2)CC(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0326,HGMMI,nisoldipine,CC1=C([C@@H](C(=C(N1)C)C(=O)OCC(C)C)c1ccccc1[N](=O)O)C(=O)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0327,HGMMI,lamotrigine,c1cc(c(c(c1)Cl)Cl)c1c(nc(nn1)N)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0328,HGMMI,atovaquone,C1C[C@@H](CC[C@H]1c1ccc(cc1)Cl)C1=C(c2ccccc2C(=O)C1=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0329,HGMMI,aripiprazole,C1CC(=O)Nc2c1ccc(c2)OCCCCN1CCN(CC1)c1c(c(ccc1)Cl)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0330,HGMMI,candesartan,CCOc1nc2cccc(c2n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0331,HGMMI,eprosartan mesylate,CCCCc1ncc(n1Cc1ccc(cc1)C(=O)O)/C=C(\Cc1cccs1)/C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0332,HGMMI,guanfacine,c1cc(c(c(c1)Cl)CC(=O)N=C(N)N)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0333,HGMMI,tizanidine,C1CN=C(N1)Nc1c(ccc2nsnc12)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0334,HGMMI,gefitinib,COc1c(cc2c(c1)ncnc2Nc1cc(c(cc1)F)Cl)OCCCN1CCOCC1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0335,HGMMI,montelukast.na,CC(C)(c1ccccc1CC[C@@H](c1cccc(c1)/C=C\c1nc2c(ccc(c2)Cl)cc1)SCC1(CC1)CC(=O)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0336,HGMMI,dofetilide,CN(CCc1ccc(cc1)NS(=O)(=O)C)CCOc1ccc(cc1)NS(=O)(=O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0337,HGMMI,erlotinib,COCCOc1c(cc2c(c1)c(ncn2)Nc1cccc(c1)C#C)OCCOC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0338,HGMMI,tacrine,C1CCc2nc3ccccc3c(c2C1)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0339,HGMMI,amiloride.hcl.2h2o,c1(c(nc(c(n1)Cl)N)N)C(=O)N=C(N)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0340,HGMMI,gabapentin,C1CCC(CC1)(CC(=O)O)CN,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0341,HGMMI,phenoxybenzamine.hcl,C[C@H](COc1ccccc1)N(CCCl)Cc1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0342,HGMMI,trifluoperazine,CN1CCN(CC1)CCCN1c2ccccc2Sc2c1cc(cc2)C(F)(F)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0343,HGMMI,clozapine,CN1CCN(CC1)C1=c2ccccc2=Nc2c(N1)cc(cc2)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0344,HGMMI,acitretin,Cc1cc(c(c(c1/C=C\C(=C/C=C\C(=C\C(=O)O)\C)\C)C)C)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0345,HGMMI,calcitriol,C[C@H](CCCC(C)(C)O)[C@@H]1CC[C@H]2[C@@]1(CCC/C/2=C/C=C\1/C[C@H](C[C@@H](C1=C)O)O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0346,HGMMI,ketoconazole,CC(=O)N1CCN(CC1)c1ccc(cc1)OC[C@H]1CO[C@](O1)(Cn1ccnc1)c1c(cc(cc1)Cl)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0347,HGMMI,cromolyn,c1cc2c(c(c1)OCC(COc1cccc3c1c(=O)cc(o3)C(=O)O)O)c(=O)cc(o2)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0348,HGMMI,bumetanide,CCCCNc1c(c(cc(c1)C(=O)O)S(=O)(=O)N)Oc1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0349,HGMMI,piroxicam,CN1C(=C(c2ccccc2S1(=O)=O)O)C(=O)Nc1ccccn1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0350,HGMMI,moxifloxacin.hcl,COc1c2c(cc(c1N1C[C@H]3CCCN[C@H]3C1)F)c(=O)c(cn2C1CC1)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0351,HGMMI,carbidopa,C[C@](Cc1cc(c(cc1)O)O)(C(=O)O)NN,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0352,HGMMI,ketoprofen,C[C@H](c1cccc(c1)C(=O)c1ccccc1)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0353,HGMMI,meloxicam,Cc1cnc(s1)NC(=O)C1=C(c2ccccc2S(=O)(=O)N1C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0354,HGMMI,terbinafine,CC(C)(C)C#C/C=C\CN(C)Cc1cccc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0355,HGMMI,raloxifene,C1CCN(CC1)CCOc1ccc(cc1)C(=O)c1c(sc2c1ccc(c2)O)c1ccc(cc1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0356,HGMMI,delavirdine mesylate,CC(C)Nc1c(nccc1)N1CCN(CC1)C(=O)c1cc2c([nH]1)ccc(c2)NS(=O)(=O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0357,HGMMI,cetirizine,C1CN(CCN1CCOCC(=O)O)[C@H](c1ccccc1)c1ccc(cc1)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0358,HGMMI,pioglitazone.hcl,CCc1cnc(cc1)CCOc1ccc(cc1)C[C@H]1C(=O)NC(=O)S1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0359,HGMMI,rivastigmine tartrate,CCN(C)C(=O)Oc1cccc(c1)[C@H](C)N(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0360,HGMMI,zileuton,C[C@H](c1cc2ccccc2s1)N(C(=O)N)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0361,HGMMI,diazoxide,CC1=NS(=O)(=O)c2c(N1)ccc(c2)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0362,HGMMI,glyburide,COc1c(cc(cc1)Cl)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0363,HGMMI,bexarotene,Cc1cc2c(cc1C(=C)c1ccc(cc1)C(=O)O)C(CCC2(C)C)(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0364,HGMMI,letrozole,c1cc(ccc1C#N)C(c1ccc(cc1)C#N)n1cncn1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0365,HGMMI,clindamycin palmitate,CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@H]([C@H](O[C@H]1SC)[C@H]([C@H](C)Cl)NC(=O)[C@@H]1C[C@H](CN1C)CCC)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0366,HGMMI,fluvastatin,CC(C)n1c2=CCCC=c2c(c1/C=C\[C@H](C[C@H](CC(=O)O)O)O)c1ccc(cc1)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0367,HGMMI,fosinopril,CCC(=O)O[C@H](C(C)C)O[P@](=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C[C@@H]1C(=O)O)C1CCCCC1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0368,HGMMI,granisetron.hcl,CN1[C@@H]2CCC[C@H]1C[C@H](C2)NC(=O)c1nn(c2ccccc12)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0369,HGMMI,atazanavir,CC(C)(C)[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](CN(Cc1ccc(cc1)c1ccccn1)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0370,HGMMI,oseltamivir phosphate,CCC(CC)O[C@H]1C=C(C[C@@H]([C@H]1NC(=O)C)N)C(=O)OCC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0371,HGMMI,pramipexole dihydrochloride monohydrate,CCCN[C@@H]1CCc2c(C1)sc(n2)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0372,HGMMI,acyclovir (acycloguanosine) zovirax,c1nc2c(n1COCCO)[nH]c(nc2=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0373,HGMMI,albendazole,CCCSc1cc2c(cc1)nc([nH]2)NC(=O)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0374,HGMMI,4-aminosalicylic acid,c1cc(c(cc1N)O)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0375,HGMMI,azithromycin,CC[C@@H]1[C@]([C@@H]([C@H](N(C[C@H](C[C@]([C@H]([C@H]([C@H]([C@@H](C(=O)O1)C)O[C@H]1C[C@]([C@H]([C@H](O1)C)O)(C)OC)C)O[C@H]1[C@H]([C@@H](C[C@H](O1)C)N(C)C)O)(C)O)C)C)C)O)(C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0376,HGMMI,buspirone,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN1CCN(CC1)c1ncccn1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0377,HGMMI,chlorpheniramine maleate,CN(C)CC[C@H](c1ccc(cc1)Cl)c1ccccn1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0378,HGMMI,thalidomide,C1CC(=O)NC(=O)[C@H]1N1C(=O)c2ccccc2C1=O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0379,HGMMI,ciprofloxacin,C1CC1n1cc(c(=O)c2cc(c(cc12)N1CCNCC1)F)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0380,HGMMI,citalopram,CN(C)CCC[C@@]1(c2c(CO1)cc(cc2)C#N)c1ccc(cc1)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0381,HGMMI,clomiphene citrate,CCN(CC)CCOc1ccc(cc1)/C(=C(\c1ccccc1)/Cl)/c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0382,HGMMI,desloratadine,C1Cc2c(ccc(c2)Cl)C(=C2CCNCC2)c2c1cccn2,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0383,HGMMI,dextromethorphan,CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1c3cc(cc1)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0384,HGMMI,diclofenac,c1ccc(c(c1)CC(=O)O)Nc1c(cccc1Cl)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0385,HGMMI,diflunisal,c1cc(c(cc1c1c(cc(cc1)F)F)C(=O)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0386,HGMMI,doxycycline monohydrate,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(c2c1cccc2O)O)O)O)C(=O)N)N(C)C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0387,HGMMI,esomeprazole,Cc1cnc(c(c1OC)C)C[S@@](=O)c1nc2c([nH]1)ccc(c2)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0388,HGMMI,estrone,C[C@@]12CC[C@@H]3[C@H]([C@@H]1CCC2=O)CCc1c3ccc(c1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0389,HGMMI,fenoprofen calcium,C[C@H](c1cc(ccc1)Oc1ccccc1)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0390,HGMMI,flurbiprofen,C[C@H](c1cc(c(cc1)c1ccccc1)F)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0391,HGMMI,furosemide,c1coc(c1)CNc1cc(c(cc1C(=O)O)S(=O)(=O)N)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0392,HGMMI,gemfibrozil,Cc1cc(c(cc1)C)OCCCC(C)(C)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0393,HGMMI,glimepiride,CCC1=C(CN(C1=O)C(=O)NCCc1ccc(cc1)S(=O)(=O)NC(=O)N[C@@H]1CC[C@H](CC1)C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0394,HGMMI,indapamide,C[C@H]1Cc2ccccc2N1NC(=O)c1cc(c(cc1)Cl)S(=O)(=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0395,HGMMI,ofloxacin,C[C@H]1COc2c3n1cc(c(=O)c3cc(c2N1CCN(CC1)C)F)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0396,HGMMI,leflunomide,Cc1c(cno1)C(=O)Nc1ccc(cc1)C(F)(F)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0397,HGMMI,loratadine,CCOC(=O)N1CCC(=C2c3c(CCc4c2nccc4)cc(cc3)Cl)CC1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0398,HGMMI,mefenamic acid,Cc1c(c(ccc1)Nc1ccccc1C(=O)O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0399,HGMMI,methimazole,Cn1cc[nH]c1=S,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0400,HGMMI,minocycline,CN(C)[C@@H]1[C@H]2C[C@@H]3Cc4c(ccc(c4C(=C3C(=O)[C@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0401,HGMMI,pentoxifylline,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(c1=O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0402,HGMMI,praziquantel,C1CCC(CC1)C(=O)N1C[C@H]2c3ccccc3CCN2C(=O)C1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0403,HGMMI,ranolazine,Cc1c(c(ccc1)C)NC(=O)CN1CCN(CC1)C[C@@H](COc1ccccc1OC)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0404,HGMMI,rimantadine,C[C@@H]([C@@]12C[C@H]3C[C@@H](C1)C[C@H](C3)C2)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0405,HGMMI,propranolol.hcl,CC(C)NC[C@H](COc1cccc2ccccc12)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0406,HGMMI,scopolamine,CN1[C@@H]2C[C@@H](C[C@H]1[C@H]1[C@@H]2O1)OC(=O)[C@H](CO)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0407,HGMMI,sulfadiazine,c1cnc(nc1)NS(=O)(=O)c1ccc(cc1)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0408,HGMMI,tamsulosin,CCOc1ccccc1OCCN[C@H](C)Cc1cc(c(cc1)OC)S(=O)(=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0409,HGMMI,terazosin,COc1c(cc2c(c1)c(nc(n2)N1CCN(CC1)C(=O)[C@@H]1CCCO1)N)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0410,HGMMI,topotecan,CC[C@@]1(c2c(COC1=O)c(=O)n1Cc3c(c1c2)nc1ccc(c(c1c3)CN(C)C)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0411,HGMMI,toremifene base,CN(C)CCOc1ccc(cc1)/C(=C(\CCCl)/c1ccccc1)/c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0412,HGMMI,tolmetin sodium dihydrate,Cc1ccc(cc1)C(=O)c1ccc(n1C)CC(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0413,HGMMI,tramadol,CN(C)C[C@H]1CCCC[C@]1(c1cc(ccc1)OC)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0414,HGMMI,trimethoprim,COc1cc(cc(c1OC)OC)Cc1cnc(nc1N)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0415,HGMMI,venlafaxine,CN(C)C[C@H](c1ccc(cc1)OC)C1(CCCCC1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0416,HGMMI,ketotifen fumarate,CN1CCC(=C2c3c(C(=O)Cc4ccccc24)scc3)CC1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0417,HGMMI,ondansetron,Cc1nccn1C[C@@H]1CCc2c(C1=O)c1ccccc1n2C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0418,HGMMI,thioridazine,CN1CCCC[C@H]1CCN1c2ccccc2Sc2c1cc(cc2)SC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0419,HGMMI,aprepitant,C[C@H](c1cc(cc(c1)C(F)(F)F)C(F)(F)F)O[C@@H]1[C@@H](N(CCO1)Cc1nc(=O)[nH][nH]1)c1ccc(cc1)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0420,HGMMI,bosentan,CC(C)(C)c1ccc(cc1)S(=O)(=O)Nc1c(c(nc(n1)c1ncccn1)OCCO)Oc1ccccc1OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0421,HGMMI,efavirenz,C1CC1C#C[C@@]1(c2c(ccc(c2)Cl)NC(=O)O1)C(F)(F)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0422,HGMMI,cyproheptadine.hcl sesquihydrate,CN1CCC(=C2c3ccccc3C=Cc3ccccc23)CC1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0423,HGMMI,abacavir,C1CC1Nc1nc(nc2c1ncn2[C@@H]1C[C@H](C=C1)CO)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0424,HGMMI,acebutolol,CCCC(=O)Nc1cc(c(cc1)OC[C@H](CNC(C)C)O)C(=O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0425,HGMMI,acetaminophen,CC(=O)Nc1ccc(cc1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0426,HGMMI,acetohexamide,CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0427,HGMMI,adefovir dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c1ncnc2N)OCOC(=O)C(C)(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0428,HGMMI,alosetron.hcl,Cc1c(nc[nH]1)CN1CCc2c(C1=O)c1ccccc1n2C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0429,HGMMI,ambrisentan,Cc1cc(nc(n1)O[C@H](C(=O)O)C(c1ccccc1)(c1ccccc1)OC)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0430,HGMMI,artemether,C[C@@H]1CC[C@@H]2[C@H]([C@H](O[C@@H]3[C@@]42[C@H]1CC[C@](O3)(OO4)C)OC)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0431,HGMMI,asenapine maleate,CN1C[C@H]2[C@@H](C1)c1c(ccc(c1)Cl)Oc1ccccc21,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0432,HGMMI,atorvastatin calcium,CC(C)c1c(c(c(n1CC[C@@H](C[C@H](CC(=O)O)O)O)c1ccc(cc1)F)c1ccccc1)C(=O)Nc1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0433,HGMMI,benztropine mesylate,CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0434,HGMMI,bisoprolol fumarate,CC(C)NC[C@H](COc1ccc(cc1)COCCOC(C)C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0435,HGMMI,brompheniramine maleate,CN(C)CC[C@H](c1ccc(cc1)Br)c1ccccn1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0436,HGMMI,butorphanol-(+)-tartrate (schedule iv),C1CC[C@]2([C@@H]3Cc4c([C@@]2(C1)CCN3CC1CCC1)cc(cc4)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0437,HGMMI,carbinoxamine maleate,CN(C)CCO[C@H](c1ccc(cc1)Cl)c1ccccn1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0438,HGMMI,cefpodoxime proxetil,CC(C)OC(=O)O[C@H](C)OC(=O)C1=C(CS[C@@H]2N1C(=O)[C@H]2NC(=O)/C(=N\OC)/c1csc(n1)N)COC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0439,HGMMI,chlorothiazide,c1c2c(cc(c1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0440,HGMMI,chlorpropamide,CCCNC(=O)NS(=O)(=O)c1ccc(cc1)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0441,HGMMI,chlorthalidone,c1ccc2c(c1)C(=O)N[C@@]2(c1cc(c(cc1)Cl)S(=O)(=O)N)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0442,HGMMI,chlorzoxazone,c1cc2c(cc1Cl)[nH]c(=O)o2,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0443,HGMMI,cilostazol,C1CCC(CC1)n1c(nnn1)CCCCOc1cc2c(cc1)NC(=O)CC2,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0444,HGMMI,cinacalcet.hcl,C[C@@H](c1cccc2ccccc12)NCCCc1cc(ccc1)C(F)(F)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0445,HGMMI,clobazam,CN1C(=O)CC(=O)N(c2c1ccc(c2)Cl)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0446,HGMMI,clomipramine,CN(C)CCCN1c2ccccc2CCc2c1cc(cc2)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0447,HGMMI,dapsone,c1cc(ccc1N)S(=O)(=O)c1ccc(cc1)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0448,HGMMI,darifenacin,C1CN(C[C@@H]1C(c1ccccc1)(c1ccccc1)C(=O)N)CCc1cc2c(cc1)OCC2,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0449,HGMMI,darunavir,CC(C)CN(C[C@H]([C@H](Cc1ccccc1)NC(=O)O[C@@H]1CO[C@H]2[C@@H]1CCO2)O)S(=O)(=O)c1ccc(cc1)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0450,HGMMI,deferasirox,C1=C/C(=c/2\[nH]/c(=C/3\C=CC=CC3=O)/n([nH]2)c2ccc(cc2)C(=O)O)/C(=O)C=C1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0451,HGMMI,demeclocycline.hcl,CN(C)[C@@H]1[C@H]2C[C@@H]3[C@H](c4c(ccc(c4C(=C3C(=O)[C@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0452,HGMMI,desipramine.hcl,CNCCCN1c2ccccc2CCc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0453,HGMMI,desvenlafaxine,CN(C)C[C@H](c1ccc(cc1)O)C1(CCCCC1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0454,HGMMI,dienogest,C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@H]1CC[C@]2(CC#N)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0455,HGMMI,diphenhydramine,CN(C)CCOC(c1ccccc1)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0456,HGMMI,disopyramide,CC(C)N(CC[C@](c1ccccc1)(c1ccccn1)C(=O)N)C(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0457,HGMMI,doxepin,CN(C)CC/C=C\1/c2ccccc2COc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0458,HGMMI,dutasteride,C[C@@]12CC[C@@H]3[C@H]([C@@H]1CC[C@H]2C(=O)Nc1c(ccc(c1)C(F)(F)F)C(F)(F)F)CC[C@H]1[C@@]3(C=CC(=O)N1)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0459,HGMMI,estropipate,C[C@@]12CC[C@@H]3[C@H]([C@@H]1CCC2=O)CCc1c3ccc(c1)OS(=O)(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0460,HGMMI,ethinyl estradiol,C[C@]12CC[C@@H]3[C@H]([C@H]1CC[C@]2(C#C)O)CCc1c3ccc(c1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0461,HGMMI,ethionamide,CCc1nccc(c1)C(=S)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0462,HGMMI,everolimus,C[C@H]1CC[C@@H]2C[C@@H](/C(=C\C=C/C=C\[C@@H](C[C@H](C(=O)[C@H]([C@H](/C(=C\[C@@H](C(=O)C[C@@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]1(O2)O)[C@H](C)C[C@@H]1CC[C@H]([C@H](C1)OC)OCCO)C)/C)O)OC)C)C)/C)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0463,HGMMI,fexofenadine,CC(C)(c1ccc(cc1)[C@H](CCCN1CC[C@@H](CC1)C(c1ccccc1)(c1ccccc1)O)O)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0464,HGMMI,fingolimod,CCCCCCCCc1ccc(cc1)CCC(CO)(CO)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0465,HGMMI,flavoxate,Cc1c(oc2c(c1=O)cccc2C(=O)OCCN1CCCCC1)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0466,HGMMI,formoterol,C[C@H](Cc1ccc(cc1)OC)NC[C@H](c1cc(c(cc1)O)NC=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0467,HGMMI,gemifloxacin,CO/N=C\1/CN(C[C@H]1CN)c1c(cc2c(=O)c(cn(c2n1)C1CC1)C(=O)O)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0468,HGMMI,hydralazine,c1ccc2c(c1)cnnc2NN,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0469,HGMMI,hydrochlorothiazide,C1Nc2cc(c(cc2S(=O)(=O)N1)S(=O)(=O)N)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0470,HGMMI,hydroflumethiazide,C1Nc2c(cc(c(c2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0471,HGMMI,hydroxychloroquine sulfate,CCN(CCC[C@H](C)Nc1c2ccc(cc2ncc1)Cl)CCO,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0472,HGMMI,hydroxyzine dihydrochloride,C1CN(CCN1CCOCCO)[C@H](c1ccccc1)c1ccc(cc1)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0473,HGMMI,indinavir,CC(C)(C)NC(=O)[C@H]1CN(CCN1C[C@H](C[C@H](Cc1ccccc1)C(=O)N[C@@H]1[C@H](Cc2ccccc12)O)O)Cc1cnccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0474,HGMMI,isocarboxazid,Cc1cc(no1)C(=O)NNCc1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0475,HGMMI,isradipine,CC1=C([C@@H](C(=C(N1)C)C(=O)OC(C)C)c1cccc2nonc12)C(=O)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0476,HGMMI,labetalol,C[C@H](CCc1ccccc1)NC[C@H](c1cc(c(cc1)O)C(=O)N)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0477,HGMMI,lacosamide,CC(=O)N[C@H](COC)C(=O)NCc1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0478,HGMMI,lamivudine,C1[C@H](O[C@H](S1)CO)n1ccc(nc1=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0479,HGMMI,lenalidomide,C1CC(=O)NC(=O)[C@H]1N1Cc2c(C1=O)cccc2N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0480,HGMMI,lopinavir,Cc1c(c(ccc1)C)OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0481,HGMMI,loxapine succinate,CN1CCN(CC1)C1=Nc2ccccc2Oc2c1cc(cc2)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0482,HGMMI,maraviroc,Cc1nnc(n1[C@@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](c1ccccc1)NC(=O)C1CCC(CC1)(F)F)C(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0483,HGMMI,meclizine dihydrochloride,Cc1cc(ccc1)CN1CCN(CC1)[C@H](c1ccccc1)c1ccc(cc1)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0484,HGMMI,meclofenamate,Cc1c(c(c(cc1)Cl)Nc1ccccc1C(=O)O)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0485,HGMMI,meprobamate,CCCC(C)(COC(=O)N)COC(=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0486,HGMMI,mestranol,C[C@]12CC[C@@H]3[C@H]([C@H]1CC[C@]2(C#C)O)CCc1c3ccc(c1)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0487,HGMMI,methazolamide,CC(=O)/N=c\1/n(nc(s1)S(=O)(=O)N)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0488,HGMMI,methenamine hippurate,c1ccc(cc1)C(=O)NCC(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0489,HGMMI,methocarbamol,COc1ccccc1OC[C@@H](COC(=O)N)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0490,HGMMI,methylergonovine maleate,CC[C@H](CO)NC(=O)[C@H]1CN([C@H]2Cc3c[nH]c4cccc(c34)C2=C1)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0491,HGMMI,metolazone,C[C@H]1Nc2cc(c(cc2C(=O)N1c1ccccc1C)S(=O)(=O)N)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0492,HGMMI,metyrapone,CC(C)(c1cnccc1)C(=O)c1cnccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0493,HGMMI,mexiletine,Cc1c(c(ccc1)C)OC[C@@H](C)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0494,HGMMI,miconazole,c1cc(c(cc1Cl)Cl)CO[C@H](Cn1ccnc1)c1c(cc(cc1)Cl)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0495,HGMMI,milnacipran,CCN(CC)C(=O)[C@]1(C[C@H]1CN)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0496,HGMMI,mirtazapine,CN1CCN2[C@H](C1)c1ccccc1Cc1c2nccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0497,HGMMI,modafinil,c1ccc(cc1)C(c1ccccc1)[S@@](=O)CC(=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0498,HGMMI,moexipril.hcl,CCOC(=O)[C@@H](CCc1ccccc1)N[C@H](C)C(=O)N1Cc2cc(c(cc2C[C@H]1C(=O)O)OC)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0499,HGMMI,nadolol,CC(C)(C)NC[C@H](COc1cccc2c1C[C@H]([C@@H](C2)O)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0500,HGMMI,naratriptan.hcl,CNS(=O)(=O)CCc1cc2c(cc1)[nH]cc2C1CCN(CC1)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0501,HGMMI,nebivolol,C1Cc2c(ccc(c2)F)O[C@H]1[C@H](CNC[C@H]([C@@H]1CCc2c(O1)ccc(c2)F)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0502,HGMMI,nortriptyline,CNCCC=C1c2ccccc2CCc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0503,HGMMI,oxtriphylline,Cn1c(c2c(ncn2)n(c1=O)C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0504,HGMMI,palonosetron.hcl,C1C[C@@H]2CN(C(=O)c3c2c(ccc3)C1)[C@@H]1CN2CC[C@H]1CC2,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0505,HGMMI,pazopanib.hcl,Cc1c(cc(cc1)Nc1nccc(n1)N(C)c1cc2nn(c(c2cc1)C)C)S(=O)(=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0506,HGMMI,pemirolast potassium,Cc1cccn2c1ncc(c2=O)c1nnn[nH]1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0507,HGMMI,perindopril erbumine,CCC[C@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0508,HGMMI,perphenazine,C1CN(CCN1CCCN1c2ccccc2Sc2c1cc(cc2)Cl)CCO,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0509,HGMMI,phenylephrine,CNC[C@H](c1cc(ccc1)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0510,HGMMI,pitavastatin calcium,C1CC1c1nc2ccccc2c(c1/C=C/[C@H](C[C@@H](CC(=O)O)O)O)c1ccc(cc1)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0511,HGMMI,posaconazole,CC[C@H]([C@H](C)O)n1c(=O)n(cn1)c1ccc(cc1)N1CCN(CC1)c1ccc(cc1)OC[C@H]1C[C@](OC1)(Cn1cncn1)c1c(cc(cc1)F)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0512,HGMMI,pravastatin,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0513,HGMMI,primidone,CCC1(C(=O)NCNC1=O)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0514,HGMMI,propylthiouracil,CCCc1cc(=O)[nH]c(=S)[nH]1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0515,HGMMI,protriptyline.hcl,CNCCC[C@@H]1c2ccccc2C=Cc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0516,HGMMI,pyrazinamide,c1cnc(cn1)C(=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0517,HGMMI,pyrimethamine,CCc1c(c(nc(n1)N)N)c1ccc(cc1)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0518,HGMMI,rabeprazole,Cc1c(ccnc1C[S@@](=O)c1nc2ccccc2[nH]1)OCCCOC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0519,HGMMI,raltegravir,Cc1nnc(o1)C(=O)NC(C)(C)c1nc(c(c(=O)n1C)O)C(=O)NCc1ccc(cc1)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0520,HGMMI,rasagiline mesylate,C#CCN[C@@H]1CCc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0521,HGMMI,reserpine,CO[C@@H]1[C@@H](C[C@@H]2CN3CCc4c([C@H]3C[C@@H]2[C@H]1C(=O)OC)[nH]c1c4ccc(c1)OC)OC(=O)c1cc(c(c(c1)OC)OC)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0522,HGMMI,rifaximin,C[C@@H]1/C=C/C=C(\C(=O)Nc2c(c3c(c4c(c(c3O)C)O[C@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@H]([C@@H]([C@@H]1O)C)O)C)OC(=O)C)C)OC)C)c1c2n2ccc(cc2n1)C)O)/C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0523,HGMMI,ropinirole,CCCN(CCC)CCc1c2CC(=O)Nc2ccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0524,HGMMI,rosuvastatin calcium,CC(C)c1nc(nc(c1/C=C\[C@@H](C[C@H](CC(=O)O)O)O)c1ccc(cc1)F)N(C)S(=O)(=O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0525,HGMMI,rufinamide,c1cc(c(c(c1)F)Cn1cc(nn1)C(=O)N)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0526,HGMMI,saquinavir mesylate,CC(C)(C)NC(=O)[C@@H]1C[C@H]2CCCC[C@H]2CN1C[C@H]([C@@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)N)NC(=O)c1nc2ccccc2cc1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0527,HGMMI,selegiline,C[C@@H](Cc1ccccc1)N(C)CC#C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0528,HGMMI,sertraline,CN[C@@H]1CC[C@H](c2ccccc12)c1cc(c(cc1)Cl)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0529,HGMMI,sitagliptin phosphate,C1Cn2c(nnc2C(F)(F)F)CN1C(=O)C[C@H](Cc1cc(c(cc1F)F)F)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0530,HGMMI,sorafenib tosylate,CNC(=O)c1nccc(c1)Oc1ccc(cc1)NC(=O)Nc1cc(c(cc1)Cl)C(F)(F)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0531,HGMMI,sunitinib malate,CCN(CC)CCNC(=O)c1c([nH]c(c1C)/C=C\1/c2c(ccc(c2)F)NC1=O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0532,HGMMI,telbivudine,Cc1cn(c(=O)[nH]c1=O)[C@@H]1C[C@H]([C@H](O1)CO)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0533,HGMMI,telithromycin,CC[C@@H]1[C@]2([C@H]([C@@H](C(=O)[C@H](C[C@]([C@H]([C@@H](C(=O)[C@H](C(=O)O1)C)C)O[C@@H]1[C@H]([C@H](C[C@H](O1)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCn1cc(nc1)c1cnccc1)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0534,HGMMI,temazepam,CN1c2c(cc(cc2)Cl)C(=N[C@@H](C1=O)O)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0535,HGMMI,terbutaline hemisulfate,CC(C)(C)NC[C@H](c1cc(cc(c1)O)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0536,HGMMI,tetrabenazine,CC(C)C[C@@H]1CN2CCc3cc(c(cc3[C@H]2CC1=O)OC)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0537,HGMMI,tiagabine,Cc1c(scc1)C(=CCCN1CCC[C@H](C1)C(=O)O)c1c(ccs1)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0538,HGMMI,tolterodine tartrate,Cc1cc(c(cc1)O)[C@H](CCN(C(C)C)C(C)C)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0539,HGMMI,tolvaptan,Cc1ccccc1C(=O)Nc1cc(c(cc1)C(=O)N1CCC[C@H](c2c1ccc(c2)Cl)O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0540,HGMMI,topiramate,CC1(O[C@H]2CO[C@]3([C@@H]([C@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0541,HGMMI,torsemide,Cc1cc(ccc1)Nc1c(cncc1)S(=O)(=O)NC(=O)NC(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0542,HGMMI,trazodone,C1CN(CCN1CCCn1c(=O)n2ccccc2n1)c1cc(ccc1)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0543,HGMMI,triamcinolone acetonide,CC1(O[C@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5([C@]4([C@H](C[C@]3([C@]2(O1)C(=O)CO)C)O)F)C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0544,HGMMI,triamterene,c1ccc(cc1)c1nc2c(nc1N)nc(nc2N)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0545,HGMMI,triazolam,c1nnc2n1c1c(cc(cc1)Cl)C(=NC2)c1ccccc1Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0546,HGMMI,trimethobenzamide,CN(C)CCOc1ccc(cc1)CNC(=O)c1cc(c(c(c1)OC)OC)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0547,HGMMI,trimipramine maleate,C[C@@H](CN1c2ccccc2CCc2ccccc12)CN(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0548,HGMMI,trospium chloride,C1CC[N+]2(C1)[C@H]1CC[C@@H]2C[C@H](C1)OC(=O)C(c1ccccc1)(c1ccccc1)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
TI0549,HGMMI,almotriptan,CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0550,HGMMI,aminoglutethimide,CC[C@@]1(c2ccc(N)cc2)CCC(=O)NC1=O,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0551,HGMMI,amisulpride,CCN1CCC[C@H]1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0552,HGMMI,antazoline phosphate,c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0553,HGMMI,atenolol,CC(C)NC[C@H](O)COc1ccc(CC(=O)N)cc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0554,HGMMI,azatadine maleate,CN1CCC(=C2c3ccccc3CCc3cccnc23)CC1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0555,HGMMI,bambuterol,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc([C@H](O)CNC(C)(C)C)c1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0556,HGMMI,betaxalol,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0557,HGMMI,buramate,O=C(NCc1ccccc1)OCCO,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0558,HGMMI,clenbuterol,CC(C)(C)NC[C@@H](O)c1cc(Cl)c(N)c(Cl)c1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0559,HGMMI,clidinium,C[N@@+]12CC[C@@H](CC1)[C@H](OC(=O)C(O)(c1ccccc1)c1ccccc1)C2,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0560,HGMMI,dabigatran etexilate mesylate,CCCCCCOC(=O)/N=C(\N)/c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0561,HGMMI,diperodon,O=C(Nc1ccccc1)OC[C@H](CN1CCCCC1)OC(=O)Nc1ccccc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0562,HGMMI,domperidone,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc23)CC1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0563,HGMMI,doxylamine succinate,CN(C)CCO[C@](C)(c1ccccc1)c1ccccn1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0564,HGMMI,eletriptan hydrobromide,CN1CCC[C@H]1Cc1c[nH]c2cc(CCS(=O)(=O)c3ccccc3)ccc12,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0565,HGMMI,ethynodiol diacetate,C#C[C@@H]1C[C@@H]2[C@H]3CCC4=C[C@@H](OC(=O)C)CC[C@H]4[C@H]3CC[C@]2(C)[C@H]1OC(=O)C,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0566,HGMMI,hyoscyamine,CN1[C@@H]2CC[C@H]1C[C@H](OC(=O)[C@H](CO)c1ccccc1)C2,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0567,HGMMI,mebhydrolin naphthalenesulfonate,CN1CCc2c(c3ccccc3n2Cc2ccccc2)C1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0568,HGMMI,meticrane,Cc1cc2c(cc1S(=O)(=O)N)S(=O)(=O)CCC2,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0569,HGMMI,mianserin,CN1CCN2c3ccccc3Cc3ccccc3[C@@H]2C1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0570,HGMMI,nefopam,CN1CCO[C@@H](c2ccccc2)c2ccccc2C1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0571,HGMMI,oxethazaine,CN(C(=O)CN(CCO)CC(=O)N(C)C(C)(C)Cc1ccccc1)C(C)(C)Cc1ccccc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0572,HGMMI,pergolide mesylate,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]12,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0573,HGMMI,pridinol methanesulfonate,OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0574,HGMMI,quinacrine,CCN(CC)CCC[C@H](C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0575,HGMMI,solifenacin succinate,O=C(O[C@H]1CN2CC[C@@H]1CC2)[C@@H]1NCc2ccccc2[C@H]1c1ccccc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0576,HGMMI,spiperone,O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0577,HGMMI,tegaserod maleate,CCCCCNC(=N)N/N=C\c1c[nH]c2ccc(OC)cc12,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0578,HGMMI,tenoxicam,CN1C(=C(O)c2sccc2S1(=O)=O)C(=O)Nc1ccccn1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0579,HGMMI,thiabendazole,c1ccc2[nH]c(c3cscn3)nc2c1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0580,HGMMI,tiapride,CCN(CC)CCNC(=O)c1cc(S(=O)(=O)C)ccc1OC,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0581,HGMMI,timolol maleate,CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0582,HGMMI,triprolidine,Cc1ccc(/C(=C\CN2CCCC2)/c2ccccn2)cc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0583,HGMMI,tropisetron,CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
TI0584,HGMMI,zolpidem,Cc1ccc(c2[nH]c3ccc(C)c[n+]3c2CC(=O)N(C)C)cc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
ES0585,HGMMS,rifampin (rifampicin),CC1C=CC=C(C(=O)NC2=C(C3=C(C(=C4C(=C3C(=O)C2=CNN5CCN(CC5)C)C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
ES0586,HGMMS,betamethasone,CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
ES0587,HGMMS,hydrocortisone acetate,CC(=O)OCC(=O)C1(CCC2C1(CC(C3C2CCC4=CC(=O)CCC34C)O)C)O,"hydrolysis, reduction",OCC(C1(O)CCC2C1(C)CC(O)C3C2CCC4=CC(CCC34C)=O)=O,OCC(C1(CCC2C1(CC(C3C2CCC4=CC(CCC34C)=O)O)C)O)O,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
ES0588,HGMMS,prednisolone,CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O,desmolysis,O=C1CCC2C1(CC(C3C2CCC4=CC(C=CC34C)=O)O)C,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
ES0589,HGMMS,paliperidone,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,unknown,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
ES0590,HGMMS,diacetamate,CC(=O)Nc1ccc(OC(C)=O)cc1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
ES0591,HGMMS,ergonovine maleate,CC(CO)NC(=O)C1C=C2c3cccc4[nH]cc(c34)CC2[N](C)C1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
ES0592,HGMMS,mevastatin,CCC(C)C(=O)OC1CCC=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
ES0593,HGMMS,nitrendipine,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C]1c1cccc([N+](=O)[O-])c1,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
ES0594,HGMMS,norethindrone acetate,C#CC1(OC(C)=O)CCC2C3CCC4=CC(=O)CCC4C3CCC21C,unknown,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
ES0595,HGMMS,Olsalazine,C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O,reduction,C1=CC(=C(C=C1N)C(=O)O)O,NONE,1983/01,Absorption and Excretion of a Single 1-g Dose of Azodisal Sodium in Subjects with Ileostomy,10.3109/00365528309181568
ES0596,HGMMS,Chloramphenicol,C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],hydrolysis,OC[C@@H](N)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1,NONE,1967/06,The bacterial degradation of chloramphenicol,10.1016/s0140-6736(67)92720-1
ES0597,HGMMS,Amaranth Acid,C1=CC=C2C(=C1)C(=CC=C2S(=O)(=O)O)N=NC3=C4C=CC(=CC4=CC(=C3O)S(=O)(=O)O)S(=O)(=O)O,unknown,NONE,NONE,2019/04,Azoreductase activity of dye-decolorizing bacteria isolated from the human gut microbiota,10.1038/s41598-019-41894-8
ES0598,HGMMS,orange II,C1=CC=C2C(=C1)C=CC(=C2N=NC3=CC=C(C=C3)S(=O)(=O)[O])O,unknown,NONE,NONE,1978/03,Reduction of azo dyes by intestinal anaerobes,10.1128/aem.35.3.558-562.1978
ES0599,HGMMS,quercetin-3-glucoside,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,hydrolysis,C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O,NONE,2000/12,Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria,10.1046/j.1365-2672.2000.01209.x
ES0600,HGMMS,ferulic acid,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,"hydrolysis, dealkylation",COC1=C(O)C=CC(CCC(O)=O)=C1,OC1=C(O)C=CC(CCC(O)=O)=C1,2011/05,High-protein reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health,10.3945/ajcn.110.002188
ES0601,HGMMS,"5,7-DMF",O=C1C2=C(OC)C=C(OC)C=C2OC(C3=CC=CC=C3)=C1,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC=CC=C3)=C1)O)OC,O=C1C2=C(C=C(C=C2OC(C3=CC=CC=C3)=C1)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
ES0602,HGMMS,"5-OH-3,7,4'-DMF",O=C1C2=C(O)C=C(OC)C=C2OC(C3=CC=C(OC)C=C3)=C1OC,dealkylation,O=C1C2=C(C=C(C=C2OC(C3=CC=C(C=C3)OC)=C1OC)O)O,O=C1C2=C(C=C(C=C2OC(C3=CC=C(C=C3)O)=C1O)O)O,2017/03,Demethylation of Polymethoxyflavones by Human Gut Bacterium Blautia sp. MRG-PMF1,10.1021/acs.jafc.7b00408
ES0603,HGMMS,Daidzein,C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3)O)O,reduction,O=C1C(C=CC(O)=C2)=C2OCC1C3=CC=C(O)C=C3,OC1=CC2=C(C=C1)CC(CO2)C3=CC=C(O)C=C3,2016/08,Phytoestrogen Metabolism by Adult Human Gut Microbiota,10.3390/molecules21081034
ES0604,HGMMS,diosmetin-7-O-glucoside,COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O,"hydrolysis, dehydroxylation",COC1=C(O)C=C(C2=CC(C3=C(O)C=C(O)C=C3O2)=O)C=C1,COC1=CC=C(C2=CC(C3=C(O)C=C(O)C=C3O2)=O)C=C1,2014/11,Determination of metabolites of diosmetin-7-O-glucoside by a newly isolated Escherichia coli from human gut using UPLC-Q-TOF/MS,10.1021/jf502676j
ES0605,HGMMS,"2,5-DNT",CC1=C(C=CC(=C1)[N+](=O)[O-])[N+](=O)[O-],reduction,CC1=C([N+]([O-])=O)C=CC(N)=C1,CC1=C(N)C=CC([N+]([O-])=O)=C1,1984/10,Metabolism of dinitrotoluene isomers by Escherichia coli isolated from human intestine,10.1248/cpb.32.4070
ES0606,HGMMS,Sertraline Carbamoyl Glucuronide,CN([C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl)C(=O)O[C@H]4[C@H]([C@H]([C@@H](C(O4)C(=O)O)O)O)O,unknown,NONE,NONE,2019/01,I-Screen: an ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent,TNO: 871815
ES0607,HGMMS,Raloxifene 4'-Glucuronide,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O,unknown,NONE,NONE,2019/01,I-Screen: an ex vivo human microbiome platform to study microbiome induced reverse metabolism of metabolites back to parent,TNO: 871815
ES0608,HGMMS,p-Coumaric Acid,C1=CC(=CC=C1/C=C/C(=O)O)O,unknown,NONE,NONE,1972/03,Metabolism of azetirelin a new thyrotropin-releasing hormone (TRH) analogue by intestinal microorganisms,10.1111/j.1600-0773.1972.tb03610.x
ES0609,HGMMS,TMAO,C[N+](C)(C)[O-],reduction,CN(C)C,NONE,2018/04,Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota,10.1186/s40168-018-0461-0
ES0610,HGMMS,potentillin,C1[C@@H]2[C@H]([C@H]3[C@H]([C@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C(=C5C6=C(C(=C(C=C6C(=O)O3)O)O)O)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
ES0611,HGMMS,stenophyllinin A,C1C([C@H](OC2=C1C(=CC3=C2C4C5C(OC(=O)C6=CC(=C(C(=C6C7=C(C(=O)C4(C7C(=O)O5)O3)O)O)O)O)C8C(COC(=O)C9=CC(=C(C(=C9C1=C(C(=C(C=C1C(=O)O8)O)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)C1=CC(=C(C=C1)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
ES0612,HGMMS,gemin A,C1[C@@H]2[C@H]([C@H]3[C@H]([C@H](O2)OC(=O)C4=CC(=C(C(=C4OC5=CC(=CC(=C5O)O)C(=O)O[C@@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O7)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)OC(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O3)O)O)O)O)O)O)OC(=O)C2=CC(=C(C(=C2C2=C(C(=C(C=C2C(=O)O1)O)O)O)O)O)O,hydrolysis,O=C1C2=CC(O)=CC=C2C3=CC=C(O)C=C3O1,O=C1C2=CC(O)=CC=C2C3=C(O)C(O)=C(O)C=C3O1,2016/12,Differences in Metabolism of Ellagitannins by Human Gut Microbiota ex Vivo Cultures,10.1021/acs.jnatprod.6b00602
ES0613,HGMMS,Ginsenoside Rg5,CC(=CC/C=C(\C)/[C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)C,hydrolysis,C/C(C)=C\C/C=C([C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]3[C@@]2(C)CC[C@@H]4[C@]3(C)CC[C@H](O)C4(C)C)\C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
ES0614,HGMMS,ginsenoside Rb1,CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)O)O)C,hydrolysis,C/C(C)=C\CC[C@@]([C@H]1CC[C@]2(C)[C@@H]1[C@H](O)C[C@H]3[C@@]2(C)CC[C@@H]4[C@]3(C)CC[C@H](O)C4(C)C)(O)C,NONE,2018/06,Gut microbiota-mediated pharmacokinetics of ginseng saponins,10.1016/j.jgr.2017.04.011
ES0615,HGMMS,Geniposide,COC(=O)C1=CO[C@H]([C@H]2[C@@H]1CC=C2CO)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O,hydrolysis,COC(C1=CO[C@@H](O)[C@H]2[C@@H]1CC=C2CO)=O,NONE,2012/03,Role of metabolism by human intestinal microflora in geniposide-induced toxicity in HepG2 cells,10.1007/s12272-012-0418-y
ES0616,HGMMS,Floxuridine,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O,unknown,NONE,NONE,2017/04,Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C. elegans,10.1016/j.cell.2017.03.040
ES0617,HGMMS,desmethyldiazepam,C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3,hydrolysis,NC1=C(C(C2=CC=CC=C2)=O)C=C(Cl)C=C1,NONE,1987/10,Degradation of bromazepam by the intestinal microflora,10.1248/cpb.35.4338
EI0618,HGMMI,clindamycin,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@H]([C@H]1[C@H]([C@@H]([C@H]([C@H](O1)SC)O)O)O)[C@H](C)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0619,HGMMI,procainamide.hcl,CCN(CC)CCNC(=O)c1ccc(cc1)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0620,HGMMI,prazosin,COc1c(cc2c(c1)c(nc(n2)N1CCN(CC1)C(=O)c1ccco1)N)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0621,HGMMI,imipramine,CN(C)CCCN1c2ccccc2CCc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0622,HGMMI,olmesartan,CCCc1nc(c(n1Cc1ccc(cc1)c1ccccc1c1n[nH]nn1)C(=O)O)C(C)(C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0623,HGMMI,metformin.hcl,CN(C)C(=N)N=C(N)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0624,HGMMI,felodipine,CCOC(=O)C1=C(NC(=C([C@H]1c1c(c(ccc1)Cl)Cl)C(=O)OC)C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0625,HGMMI,ibuprofen,CC(C)Cc1ccc(cc1)[C@H](C)C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0626,HGMMI,tranylcypromine hemisulfate,C1[C@H]([C@H]1N)c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0627,HGMMI,etoposide,C[C@H]1OC[C@H]2[C@@H](O1)[C@H]([C@H]([C@@H](O2)O[C@H]1[C@H]2COC(=O)[C@H]2[C@H](c2cc3c(cc12)OCO3)c1cc(c(c(c1)OC)O)OC)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0628,HGMMI,lapatinib ditosylate,CS(=O)(=O)CCNCc1ccc(o1)c1cc2c(cc1)ncnc2Nc1cc(c(cc1)OCc1cc(ccc1)F)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0629,HGMMI,zafirlukast,Cc1ccccc1S(=O)(=O)NC(=O)c1cc(c(cc1)Cc1cn(c2c1cc(cc2)NC(=O)OC1CCCC1)C)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0630,HGMMI,cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C1)CC=C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0631,HGMMI,vinorelbine,CCC1=C[C@H]2C[C@@](c3c(CN(C2)C1)c1ccccc1[nH]3)(c1c(cc2c(c1)[C@]13CCN4[C@H]1[C@](C=CC4)([C@H]([C@]([C@@H]3N2C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0632,HGMMI,carbamazepine,c1ccc2c(c1)C=Cc1ccccc1N2C(=O)N,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0633,HGMMI,chloroquine diphosphate,CCN(CC)CCC[C@H](C)Nc1c2ccc(cc2ncc1)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0634,HGMMI,clarithromycin,CC[C@@H]1[C@]([C@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@H]([C@H](C(=O)O1)C)O[C@@H]1C[C@]([C@H]([C@H](O1)C)O)(C)OC)C)O[C@@H]1[C@@H]([C@H](C[C@H](O1)C)N(C)C)O)(C)OC)C)C)O)(C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0635,HGMMI,amitriptyline.hcl,CN(C)CCC=C1c2ccccc2CCc2ccccc12,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0636,HGMMI,gatifloxacin,C[C@@H]1CN(CCN1)c1c(cc2c(c1OC)n(cc(c2=O)C(=O)O)C1CC1)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0637,HGMMI,nefazodone,CCc1nn(c(=O)n1CCOc1ccccc1)CCCN1CCN(CC1)c1cc(ccc1)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0638,HGMMI,nystatin,C[C@@H]1/C=C/C=C/CC/C=C\C=C\C=C\C=C/[C@@H](C[C@@H]2[C@@H]([C@@H](C[C@](O2)(C[C@H]([C@H](CC[C@@H](C[C@@H](C[C@@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]1[C@H]([C@H]([C@H]([C@H](O1)C)O)N)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0639,HGMMI,nelfinavir mesylate,Cc1c(cccc1O)C(=O)N[C@@H](CSc1ccccc1)[C@@H](CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0640,HGMMI,tamoxifen citrate,CC/C(=C(\c1ccccc1)/c1ccc(cc1)OCCN(C)C)/c1ccccc1,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0641,HGMMI,acrivastine,Cc1ccc(cc1)/C(=C\CN1CCCC1)/c1cccc(n1)/C=C\C(=O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0642,HGMMI,cefditoren pivoxil,Cc1c(scn1)/C=C\C1=C(N2[C@H]([C@H](C2=O)NC(=O)/C(=N\OC)/c2csc(n2)N)SC1)C(=O)OCOC(=O)C(C)(C)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0643,HGMMI,lansoprazole,Cc1c(ccnc1C[S@](=O)c1nc2ccccc2[nH]1)OCC(F)(F)F,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0644,HGMMI,mepenzolate,C[N+]1(CCC[C@H](C1)OC(=O)C(c1ccccc1)(c1ccccc1)O)C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0645,HGMMI,orciprenaline,CC(C)NC[C@H](c1cc(cc(c1)O)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0646,HGMMI,mitotane,c1ccc(c(c1)[C@H](c1ccc(cc1)Cl)C(Cl)Cl)Cl,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0647,HGMMI,oxytetracycline.hcl,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(c2c1cccc2O)O)O)O)C(=O)N)N(C)C)O)O,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0648,HGMMI,rifapentine,C[C@H]1/C=C/C=C(\C(=O)NC2=C(c3c(c(c4c(c3C(=O)/C/2=C/NN2CCN(CC2)C2CCCC2)C(=O)[C@](O4)(O/C=C\[C@H]([C@H]([C@H]([C@H]([C@H]([C@H]([C@@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C,NONE,NONE,NONE,2020/06,Personalized Mapping of Drug Metabolism by the Human Gut Microbiome,10.1016/j.cell.2020.05.001
EI0649,HGMMI,phenacetin,CCOc1ccc(NC(=O)C)cc1,NONE,NONE,NONE,2019/06,Mapping human microbiome drug metabolism by gut bacteria and their genes,10.1038/s41586-019-1291-3
